n/a
full list rate price target
earn report pleas see tabl
separ path hc servic
initi coverag health servic neutral industri view
among fourteen compani coverag univers two stock rate
underweight seven stock rate equal weight five stock rate overweight
break fourteen compani six key subsector discuss
detail throughout report
initi coverag six pharmaceut suppli channel stock five equal
weight rate one overweight common theme among major
compani pharmaceut suppli channel price pressur margin
compress preval past year like continu
stem combin rise price competit among exist
particip thank declin volum growth advent new competit
forc mani subsector particularli amazon drug distributor particular
continu plagu highli deflationari environ gener drug
trump administr maintain clear-cut focu reduc price
brand drug could neg impact compani pharma suppli
channel initi
express script esrx walgreen equal weight rate
one overweight diplomat dplo specialti brand drug dispens
essenti immun gener price trend amazon threat abl
leverag faster-than-averag rx volum relat biotech sector particular
initi coverag three diversifi manag care organ mco
overweight rate track sector sinc seem
bellweth top pick unitedhealth group track continu
decades-old goal ep growth given star align
medicar franchis well leverag optum also see
well-posit commerci govern membership momentum coupl
extra kicker bn pharmaci save unlock start
final believ ci continu see strength commercial/
specialti offer three compani pois leverag favor secular trend
term price margin corpor tax reduct rise interest rate via
greater invest incom inde view manag key industri select
period rise interest rate preval
mix bag medic dental distribut manufactur within
coverag univers perhap greatest amount price pressur risk margin
compress exist medic dental distribut sector initi
underweight rate owen minor patterson compani
equal weight henri schein howev
optimist dental manufactur thu initi overweight align
technolog equal weight
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn estim report
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
suppli chain pictur
four compon pharma suppli channel growth
dental/medical/vet distributor manufactur
proprietari survey gaug dental trend sentiment us europ
driver revenu price reimburs
driver medic trend
strateg intersect pharmaci manag reunit
correl fundament stock perform
initi coverag compani health servic industri neutral view
break six subsector evalu key metric
posit manag subsector three three compani
rate overweight ci due favor outlook commerci
govern health plan profit growth posit leverag rise interest
rate corpor tax reform also analysi pbm busi within mco
least posit medical/dent distributor two stock rate
underweight one equal weight due margin risk
amazon overhang survey work report suggest amazon may grab
neutral drug distribut subsector three equal weight stock
due continu drug price overhang gener deflat still
brand rx price risk trump administr agenda
posit dental manufactur due consist demand trend major
orthodont share shift clear align tradit brace overweight
neutral retail pharmaci rate equal weight due overli
competit front-end market multi-year neg comp amazon-rel risk
within pbm/specialti pharmaci overweight dplo biotech secular growth
still flourish equal weight esrx due increasingli competit pbm market
initi coverag
cardin
equal
healthcar distribut like
initi coverag eleven compani healthcar distribut sector
fairli cautiou stanc common theme among major compani price
pressur margin compress preval past year like
continu throughout stem combin intens price
competit among exist competitor due volum pressur well grow
preval new competit forc mani subsector amazon particular
among compani initi coverag two stock rate underweight
seven stock rate equal weight two stock rate overweight break eleven
compani five key subsector pharmaceut distribut retail
pharmaci pbm/specialti pharmaci dental manufactur distribut
medic distribut discuss detail throughout report
initi coverag cardin health
equal weight rate drug distribut sector
appear amazon crosshair enter healthcar suppli channel howev
industri continu plagu highli deflationari environ gener drug
compris roughli two-third profit industri core oper base
seri channel check expect gener deflat price trend persist
high-singl digit throughout leav three compani challeng
grow ebit year trump administr maintain clear-cut focu
reduc price brand drug like neg impact one-third
drug distributor ebit extra kicker group press articl
suggest walgreen held preliminari discuss
rest
alreadi wsj walgreen made take-over
approach februari believ larg
price share given premium valuat cardin
acquir
pbm segment initi coverag express script esrx equal
weight rate roll-off may still creat risk scale reduc leverag
compani core oper key whether esrx grow rx claim organ
difficult recent year may becom challeng sever
manag compani increas push share pbm market good
news pbm busi model less suscept brand gener drug
price pressur model pharma suppli channel pbm actual exist
reduc drug cost major drug price inflat and/or deflat get pass
payor
retail pharmaci segment initi coverag walgreen boot allianc
equal weight rate stock trade lower end
histor valuat rang believ investor unlik rerat multipl higher
year amazon threat higher-margin front-end wba retail franchis
forefront invest thesi inde walgreen post neg same-stor
sale comp front-end store base six consecut quarter
eight last nine quarter believ directli relat grow competit
pressur amazon among other estim front-end oper account
gross profit store base walgreen somewhat buffer
 pressur thank boot pharmaci ownership mainli
geograph diversif help moment compani post neg
initi coverag
pure-play publicli
provid overweight
ebit trend year-over-year four last five quarter retail pharmaci
segment expect segment ebit remain y-o-i
final potenti acquisit rest report press
could accret walgreen see accret analysi walgreen section
report believ also less like get investor excit strateg
perspect due overhang drug distribut sector coupl
fact walgreen alreadi captur much easi synergi gener
procur thank particip wbad drug purchas allianc
almost five year
gener posit specialti pharmaci industri initi coverag
diplomat pharmaci dplo overweight rate believ environ
industri construct trump administr comment bring
cost brand drug serv risk factor diplomat pharmaci
pure-play publicli trade specialti pharmaci provid still pois leverag
robust rx volum growth biotech regardless short-term headlin risk regard
price well dplo share rebound follow overhang so-
call direct indirect remuner dir fee charg pbm provid
dispens drug persist throughout result believ worst
regard pbm aggress tactic toward specialti pharmaci provid
dir fee believ diplomat begin gener posit organ ebitda
growth like acceler beyond
medic dental distribut manufactur
within coverag univers perhap greatest amount price pressur risk
margin compress exist medic dental distribut sector
constrain past year soft organ volum trend among custom
dental volum growth weaken rang rang
hospit volum flat quit time physician offic volum
remain bit posit mid-single-digit growth rang respons
publicli trade compani group becom bit aggress head-to-
head price competit attempt gain volum market share off-set softer
industri trend howev caus margin compress minim shift
market share either hospit distribut dental distribut top
amazon offici enter dental distribut space pois enter
hospit and/or physician offic distribut space survey work suggest amazon
inde go gain market share essenti area
addit sever lawsuit dental distribut sector past coupl year
alleg price collus among publicly-trad compani attempt
artifici sustain margin elev level within sector februari
 feder trade commiss ftc file complaint three largest
dental distributor alleg compani conspir refus serv give
discount dental buy group three compani sell bn
glove cement chair product dentist purchas year
complaint file ftc intern court trial set begin octob
backdrop initi coverag hospit distributor owen minor
dental distributor underweight rate henri
schein well-manag compani continu flourish
veterinari distribut physician offic distribut oper also
distribut busi unfortun compani still deal
dental meaning size
overhang state dental distribut oper thu initi
coverag schein equal weight rate
also initi coverag two dental manufactur compani dentspli sirona
compani fairli immun
overhang mention dental medic suppli channel see virtual
risk either compani amazon industri price pressur legal overhang
howev initi coverag equal weight rate
broad-bas manufactur dental consum equip product
expos dental sector soften volum trend face uncertainti relat host
manag chang fairli richli valu rel near-term growth prospect
contrast quit posit clear align market initi coverag
overweight rate align technolog clear-cut leader global clear
align market invisalign franchis believ becom new gold
standard global orthodont marketplac good news
earli stage potenti major shift away tradit metal bracket-and-wir brace
clear align still less market share global forese
year potenti hit long-term project growth rate fairli
high likelihood growth could exceed next year also key
patent invisalign franchis run may allow compani
keep industri lead posit us clear align market minim price pressur
year final forecast organ growth next sever
year intern penetr rat even lower
amazon threat becom realiti healthcar distribut
last year shadow amazon loom larg healthcar
distribut sector numer news outlet indic amazon either look
get involv variou subsector within space offici enter
major news headlin began may cnbc report amazon
look potenti enter pharmaci benefit manag pbm busi alongsid
hire pbm relat personnel june amazon announc acquisit
whole food would give compani first major retail footprint albeit small
rel larger food retail retail pharmaci still acquisit prompt
specif discuss either amazon media regard pharmaci dispens
and/or pharmaci benefit manag juli amazon hire execut
led healthcar life scienc group octob amazon file variou
drug/med wholesal licens howev unclear wholesal licens
specif pharmaceut product medic product potenti also
octob cnbc report amazon expect announc detail
pharmaci market strategi thanksgiv led mani stock coverag
univers under-perform octob novemb howev amazon still hadnt
announc anyth end stock began recov
decemb earli amazon continu hire healthcar relat posit
recent hire hipaa complianc relat potenti particip new
initi amazon
amazon jp morgan berkshir hathaway join forc
amazon greater foray healthcar space seemingli confirm late januari
offici announc amazon jp morgan berkshir
hathaway compani would combin forc creat stand-alone nonprofit
healthcar compani mission lower health care cost news caus stock
number healthcar subsector trade base press articl unnam
nonprofit healthcar compani would initi target technolog solut simplifi
healthcar system overarch goal reduc healthcar cost three
parent compani particular addit announc three specif execut
spearhead develop new entiti todd comb invest
manag berkshir hathaway beth galetti svp human amazon
former vice-president plan engin oper marvel sullivan
berchtold manag director jp morgan former global head novarti
new entiti would focus sole amazon berkshir jp morgan us
employe healthcar cost threat healthcar servic compani coverag
univers may mute forese futur
detail remain rel scant initi beyond initi announc
format not-for-profit compani exact target new compani
within healthcar remain unclear healthcar space could impact given
compani initi focu target technolog solut howev mani tool
servic offer publicly-trad hcit compani cornerston healthcar
cost reduct indirectli provid effici within system
believ less like major hcit compani concern around
near term hc provid may theoret lose sinc reduc medic
cost primari mission new entiti healthcar payor stock also hit
news given manag care organ mco make small profit
nowaday commerci health insur market administr servic
believ mco crosshair new amazon initi either
final seem healthcar suppli channel would unaffect particular
news given fact amazon broaden overal healthcar initi
occasion investor pressur entir healthcar servic sector may persist howev
import put amazon threat perspect time frame standpoint
addit compet retail pharmaci front-end busi
subsector coverag amazon current establish presenc
dental medic distribut area describ greater detail
contrast pharmaceut suppli channel either distribut dispens
current within amazon announc busi initi make sens given
rel higher margin current enjoy medic dental sector exist
compani margin drug distribut fairli miniscul continu
believ drug distribut busi crosshair amazon
amazon move dental space mouth mouth
discuss amazon offici enter dental medic distribut
space specif discuss consult indic dental
practition util amazon purchas not-in-mouth product consult
believ current util amazon stand current purchas although
believ amazon share closer contrast practition
unlik util amazon in-mouth product due uncertainti around qualiti
howev consult indic amazon develop relationship key
manufactur may help steer traffic amazon away tradit dental
distributor beyond consult seen amazon establish presenc dental
show specif greater new york dental meet past year
separ dental distributor voic concern amazon document cite
on-going litig base court file manag
dental distribut compani quot indic concern regard
margin compress amazon enter dental market dental distributor believ
amazon current lack servic value-add offer would like limit amazon
peripher supplier oppos broad-bas primari supplier relat
comprehens need dental practic exampl relat instal
mainten dental equip current major distributor employ train technician
fix issu amazon servic immedi avail addit
primari distributor note products/sku avail amazon
discuss greater detail later report recent conduct comprehens
dental market survey perhap one critic question ask survey
respond expect relat purchas dental consum product
amazon percent consum purchas amazon indic
line heard consult higher dental
distributor indic importantli beyond respond expect
percentag consum product purchas amazon increas
low doubl digit rang afterward respond expect increas purchas
amazon mid rang remain earli
seemingli strong interest/trend move procur dental consum
amazon could neg impact tradit dental distributor move forward
 dental consum product expect purchas amazon
amazon move hospit distribut physician offic
medic distribut busi also suscept amazon competit amazon
alreadi establish presenc margin slightli less robust
dental space medic suppli channel still boast margin superior
pharmaceut suppli channel case hospit suppli distribut
physician offic distribut consult spoken seen amazon
hospit space meaning way yet howev given amazon inde alreadi
particip area carri numer basic consum product
necessarili attach equip see medic suppli area
suscept amazon moreov amazon high level convers
custom owen minor cardin hospit distribut busi
seemingli encroach medic territori describ detail
recent wsj articl paint bleak pictur exist hospit suppli distributor
wall street journal report februari amazon push turn nascent
medical-product busi major supplier hospit outpati clinic
purchas consum product amazon barclay servic
could compet distributor item rang gauz hip implant wsj
articl state amazon invit hospit execut seattl headquart
sever occas recent late januari sound idea expand
btob marketplac one hospit could shop stock
outpati locat oper suit emerg room accord hospit
execut attend meet amazon recent dispatch employe larg
midwestern hospit system offici test whether use amazon
busi order health suppli system roughli outpati facil
accord hospit offici overse effort pilot custom
hospit system catalog suppli allow employe compar price system
negoti distributor amazon busi marketplac
articl goe state respons question effort cite
amazon build technolog serv healthcar custom seek sell hospit
marketplac concept differ typic hospit purchas conduct
contract distributor manufactur chri holt leader global
healthcar amazon busi said amazon wont look imit establish model
alreadi use medic distribut sector instead amazon goal someth
new exist supply-chain option date nearli safe secur need
clinic item
provid balanc perspect articl also discuss challeng
amazon face specif note hospit reluct buy
suppli amazon busi reason includ lack option lack control
purchas ship hospit close safeguard ensur prompt arriv
good ensur continu product suppli also critic familiar specif
import practition contrast jump on-line look best deal could
disrupt continu variabl one larg hospit system particular
northwel health new york state readi move current model
product procur clear articl whether conclud
northwel execut attend seattl meet amazon
articl also state northwel open competit market
beyond wsj articl survey physician practic survey indic
collect group physician purchas approxim consum
product amazon respond expect purchas
medic practic consum product amazon
 physician practic survey consum purchas amazon
amazon move retail pharmaci space
retail pharmaci space also suscept amazon threat amazon
made mention establish prescript pharmaci within recent acquir
whole food oper continu concern compani may move
toward busi model point locat amazon acquir pale
comparison locat walgreen oper
mute potenti impact establish retail pharmaci insid whole food store
addit compani would need gain access pbm network may
necessarili happen pbm express script would welcom amazon pharmaci
network partner valu proposit attract express script client given
amazon primarili on-line order deliveri busi model easier see enter
mail-ord pharmaci busi would make materi expans brick-
and-mortar store inde abil consum order over-the-counter medic
item on-line amazon alreadi pressur front-end busi major
retail pharmaci describ detail later report
safeti manufactur hard replic servic
gener seem busi model safeguard come amazon
particularli area autom improv exist process and/or margin
inexplic high current major oper variou busi model howev one
area within coverag univers see safeguard amazon within
healthcar manufactur busi specif see two dental manufactur
compet subsector rel insul threat amazon due
uniqu product set and/or intellectu properti denstpli sirona align
technolog two shield compani within healthcar
distribut coverag univers amazon threat asid manufactur one servic
model may addit barrier specialti pharmaci aka specialti drug
dispens market special handl drug biotech manufactur
patient consult compon servic end custom requir viabl
two shield
compani coverag
amazon threat
consum product expect purchas amazon barclay servic
one major shift occur past year within healthcar suppli chain
consolid within space combin ancillari area largest deal
current progress offici announced/propos merger
manag retail pharmaci chain one umbrella propos merger would
first kind healthcar distribut sector asid propos merger
view major major recent transact either
propos and/or complet healthcar distribut channel necessarili
innov instead conceptu mean combat price pressur
and/or margin compress due competit forc
price pressure/margin compress impetu major consolid
walgreen complet merger allianc boot toward end
final purchas outstand stake allianc boot initi stake
allianc boot acquir walgreen also propos acquir
deal eventu scrap due anti-trust concern eventu walgreen
settl scale acquisit rite aid saw compani purchas
store still progress
vertic integr within medic distribut busi
acquisit medic product manufactur asset includ cordi
asset purchas johnson johnson recent acquisit
patient recoveri medic product manufactur busi
acquir celesio europ
script acquir evicor discuss greater detail
script section report
drug procur save reduc cog also critic factor collabor
term drug procur partnership three major entiti
abc/esrx/wba partner togeth develop corp
wbad current largest gener drug sourc entiti health
cardin partner gener drug procur via red oak
offici partner gener procur via claruson
also consolid gener volum custom purpos
procur save well includ rite aid retail discuss
gener procur partnership greater detail compani section report
suppli chain pictur
figur figur provid high level view pharmaceut suppli chain
interact variou subsector suppli chain brand
drug perspect gener drug perspect
explan suppli chain dynam
follow section discuss reimburs price mechan happen
payor pbm manufactur pharmaci first import defin
term averag wholesal price awp publicli set price util reimburs
purpos awp rate gener refer percentag awp wholesal
acquisit cost wac typic awp transact involv drug
distributor allow cost price pbm reimburs
pharmaci specif gener drug list proprietari pbm could
multipl list reimburs determin addit state
govern program could also list
drug distributor compani oper wac schemat price
essenti distributor purchas product manufactur wac price less
discount list price set manufactur brand product
compani gener earn small spread hypothet exampl brand
product wac price distributor would purchas product manufactur
discount distributor would sell product retail pharmaci
wac minu pocket differ gross profit gener product
situat would occur differenti discount would greater
magnitud due distributor abl extract greater discount return market
move pbm rebat brand product usual percentag
awp particular drug gener work assumpt rebat
greater awp exampl brand drug rebat amount
would pbm would retain rebat pass
remaind back payor
context network re-bil spread pbm pay pharmaci percentag
discount awp could awp minu brand product
exchang inclus pharmaci network pbm also charg payor
differ awp rate hypothet brand product exampl pbm would charg
payor awp minu reimburs pharmaci awp minu
pocket differ servic gener spread narrow significantli
time
within context gener product percentag awp would significantli
larger profit deriv pbm depend upon purchas econom etc
compar brand product rebat would part discuss relat
retail pharmaci purchas product drug distributor dispens patient
reimburs pbm first let assum awp price wac
price pharmaci purchas product drug distributor price wac minu
prescript dispens pharmaci reimburs awp minu
therefor pharmaci pocket gross profit gross profit
gener side pharmaci reimburs awp base arrang
base arrang awp base arrang reimburs
base awp updat awp gener lag market movement price
allow arbitrag declin price gener gener goe
multi-sourc larg declin price pharmaci tend make greater
profit due lower cog rel level reimburs base
reimburs price reimburs level set pbm fluctuat
market crimp margin
brand gener convers profit exampl
figur provid sampl econom gener product compar
brand product variou player chain also show econom
gener manufactur enter market seen profit brand
product gener low player suppli chain brand product goe
gener howev profit begin improv substanti exclus
limit sourc phase supplier distributor tend make profit dollar
valu gener still rel high distributor move market share
extent extract greater discount howev drug move multi-sourc
phase supplier profit gener drug begin declin gross
margin profil gener stay absolut dollar valu begin declin
phenomenon occur gener market past year due high
gener deflat pharmacies/pbm initi launch gener provid modestli
higher profit compar brand product howev product
move multi-sourc phase greater amount profit made due
sharp declin price number manufactur enter market
turn allow pharmacies/pbm purchas lower cost continu reimburs
higher level reimburs rate resets/catch
four compon pharma suppli channel growth
think pharmaceut suppli chain macro factor within
industri drive revenu profit growth vari subsector gener key
factor drug price brand gener product new gener launch
underli market growth relat prescript rx util market share via
custom win loss follow section discuss key variabl
brandedeconomicsaverag brand drug drug drug drug gener profit brand druggener econom base number gener manufactur barclay servic
drug price environ trend less favor direct
drug distributor gener expect brand price rang higher view
gener seen prior year doubl digit expect
seen prior level brand drug inflat inde come drug
distributor suggest see brand price increas averag
drug see price increas quarter compar period saw
drug averag price increas
perhap import brand price increas januari major price
increas tend occur particularli light brand manufactur indic
would take one price increas year januari amount drug see
price increas well histor norm brand drug see price
increas month despit number drug see price increas averag
price increas gener in-lin expect drug
distributor februari drug averag price increas
brand price increas top drug sale
pharmaceut suppli chain gener price continu area concern
investor gener price data suggest gener price remain pressur
latter half despit eas comp howev gener manufactur
industri undertaken recent action may help stabil gener price
specif variou manufactur announc shutter manufactur plant
discontinu unprofit gener product high profil teva
one largest gener manufactur world announc compani
would ration manufactur capabl reduc capac beyond teva
manufactur endo pharmaceut sandoz lupin indic
manufactur would reduc variou restructur plan put motion
brand drug price inflat trend top drug sale priceavg priceavg priceavg priceavg priceavg barclay servic
declin gener price hamper profit drug distributor last two
year howev gener price re-infl stabil somewhat would like
benefici drug distributor convers hyperinfl occur gener
product may weigh player downstream retail pharmaci
recal period due hyperinfl gener product publicli
trade retail pharmaci saw gross margin compress due reimburs pressur
coincid hyperinfl expect see hyper inflat result
manufactur capac reduc gener manufactur inflat
pick level seen hyperinflationari period would detriment
figur provid year year chang gener price seen gener
price continu trend low mid-teen rang y-o-i januari
follow y-o-i trend decemb y-o-i novemb
base compani commentari recent investor confer price
gener manufactur continu declin doubl digit rang correl
commentari drug distributor drug distributor defin deflat differ
respect book busi indic
buy-sid price price gener manufactur distributor trend
high end gener deflat rang guidanc
indic gener deflat mid singl digit rang howev sell-sid
price price pharmacy/end custom distributor
provid gener deflat assumption/view comp theoret get easier
calendar new gener pipelin
follow excerpt barclay research publish specialti pharmaceut
sever price eros led mani manufactur engag signific portfolio
ration heard commentari sandoz decis reduc solid
oral dose portfolio help stabil product mood associ
access medicin formerli gpha annual meet somber felt improv
last year anecdot heard mani manufactur win anda
approv launch product clearli speak level price fallen
give us increment hope impact fda approv note
anda review fda catalyst anoth leg impact
econdisc join wbad concern feedback suppli chain
consult suggest less impact walmartmckesson see gener monthli
tsao also publish gener price monitor present monthli price data us
market januari gener price monitor februari recent note
tsao present variou gener price trend month base analysi
proprietari price data believ give accur represent
dynam industri versu wac januari overal saw gener deflat
y/i base gener product ndc howev major dichotomi
price trend compar oral solid gener vs inject gener immedi releas
ir solid oral product declin year-over-year extend releas er solid oral
gener product declin y-o-i howev inject gener continu show
categori price strength increas y-o-i inflat inject driven
select number product includ lidocain inj diazepam inj
implic gener oral vs inject price breakdown suppli chain
unfortun major compani cover pharmaceut suppli
channel exposur relat primarili oral solid gener retail
channel major inject particularli individu inject product
cite primarili dispens hospit set price typic directli
gener manufactur one except lesser degre
may captur benefit price increas specialti drug
distribut oper clinic physician final note gener price trend
oral solid inject new earli fairli
consist past year
separ price iqvia also monitor gener drug inflat track
number gener product wit price increas
hyperinfl gener real potenti profit driver drug distributor seen
figur number gener drug see price increas diminish significantli
earli vs period gener inflat elev
gener drug see price increas repres billion prior year
sale major product see price increas within inject market
shortag compar oral solid market inde januari
price increas gener product see price increas repres
billion prior year sale half within inject class
number gener wac price chang
hospit band togeth manufactur gener may easi
asid price declin discuss gener drug custom look
band togeth manufactur essenti gener product januari
intermountain healthcar ascens health ssm health triniti health announc
work togeth us depart veteran affair creat non-profit
entiti manufactur essenti gener drug directli via sub-contract
announc seemingli earli stage presum hospit would target essenti
gener product seen greatest amount hyperinfl could put
pressur market oral solid gener product seemingli seen largest
amount deflat last year inject gener product
seemingli remain firm and/or inflat given compani oper non-profit
entiti believ product compani manufactur could significantli
gener manufactur although unclear type scale compani
could build altogeth pressur gener market could
reverber throughout suppli chain view see hospit
band togeth gener manufactur major game changer industri
tradit first-tim gener launch pipelin one main driver profit
growth pharmaceut suppli chain drug distributor compani gener
gener greatest amount profit exclus period industri
definit typic two manufactur supplier gener product avail
marketplac one paragraph iv gener per fda plu author gener case
allow drug distributor extract greater absolut dollar discount
preval manufactur marketplac end retail pharmaci
gener greater gross profit product move multi-sourc period
industri definit three gener manufactur supplier given
gener product marketplac distributor tend earn lower profit multi-
sourc period tend make compar buy-sel percentag spread
smaller dollar base gener price declin greater suppli
contrast pbm via mail-ord also mani retail pharmaci dispens gener
drug awp-bas reimburs scheme gener greater profit
number gener drug wac price chang ofnumb ofnumb ofnumb ofpriornumb ofpriornumb ofpriornumb ofpriornumb priceyear priceyear priceyear priceyear priceyear salesmonthchangesmonthchangesmonthchangesmonthchang bilmonthchang bilmonthchang bilmonthchang bilmonthchang barclay servic
multi-sourc period due sale price remain fix awp-bas percentag
cost gener drug inventori decreas supplier therebi allow drug
dispens retail pbm via mail-ord captur greater econom
glori day gener launch calendar may behind us
first-tim gener launch pipelin benefici entir pharmaceut
suppli channel past year raw dollar amount tradit nda brand
drug wit gener entrant market rel softer
compar prior period like curtail profit growth prospect new
gener launch major compani pharma suppli channel
term new gener launch period expect see
bn brand drug go gener base barclay healthcar team estim
compar prior five year period saw gener launch bn
mention gener launch exclus gener benefici drug
distributor howev period estim
brand drug go gener exclus compar period
saw new gener launch exclus sale take altogeth
rel smaller profit pool stem new gener launch
annual major drug patent expir gener launch gener gener sale sale sale sale gener feethinyl estradiol/northindronewarn gener launchesacticlatedoxycyclin hydrochloridealconallerg gener launcheseffientprasurgrel gener mg weekli glatiramertevamultipl barclay servic
annual major drug patent expir gener launch gener gener sale sale sale sale gener launchessolodyn gener launchesadcircatadalafillillypulmonari siroxnovartischron iron singl gener launchesadvair arteri xrmemantin hfaalbuterol gener launchescanasamesalamineaptalisulcerit lombey acetatejannssenprost barclay servic
annual major drug patent expir gener launch gener gener sale sale sale sale gener sustennapaliperidon uric annual major drug patent expir gener launch gener gener sale sale sale sale gener transderm strip buprenorphine/nalaxonereckitt annual major drug patent expir gener launch gener gener sale sale sale sale transderm etexilateboehring ingelatri annual major drug patent expir gener launch gener gener sale sale sale sale xrmetformin barclay servic
fda backlog gener drug applic
one key factor gener drug price pace anda
approv fda period signific shortag rel
gener approv time frame coupl variou plant closur
allow signific gener hyperinfl bolu drug distributor
detriment retail pharmaci move throughout fda
began approv greater amount older gener product alongsid return close
manufactur plant led product enter market caus
recent strong gener deflat marketplac within oral solid difficult
determin fast fda approv new gener product expect
anda approv gener price declin persist
iqvia rx data trend soft slight uptick earli
one persist trend throughout somewhat soft util trend
prescript data base iqvia data saw essenti flat adjust prescript
growth compar prescript growth look retail
channel specif volum soft adjust basi prescript
volum growth throughout compar growth within
market adjust prescript volum growth moder growth
compar growth mail channel seemingli stabil back half
data chang mail order data iqvia captur led data
show signific declin adjust prescript
volum growth mail channel
take data altogeth seem util somewhat mute throughout year
phenomena publicli trade pharmaci benefit manag cite
throughout year addit gener volum suppli chain make
major profit also mute adjust gener volum
compar growth unclear persist chang
healthcar law fewer live cover seemingli control util member
could mute growth howev januari see pickup
may relat strong flu season
fda gener drug applic anda backlog analysistim receiv action completedrefus receiv final anda tent tent final complet drug master file period end anda barclay servic
past sever year pharmaci partner directli drug distributor
combin purchas power establish gener purchas consortium
three key consortium first walgreen boot allianc develop gmbh wbad
compris walgreen allianc boot recent
script second red oak sourc compris cardin health health
retail pharmaci oper third claruson compris
metric look retail pharmaci store sale prescript
volum growth key differ player market recal walgreen
partner current partner
partner seen figur store volum seemingli
quit robust throughout although note due key
contract win occur health rite aid
consist lose prescript volum throughout believ
due pend cancel deal wba/rad addit
slowdown may also due compani decis particip
prefer pharmaci within larg major medicar part plan
one key growth area term prescript growth medicar figur
highlight largest medicar part plan particip pharmaci exclud
medicar network plan could prefer pharmaci lower
co-pay etc go prefer pharmaci import monitor
win and/or lose share marketplac given medicar member high
util member compar normal popul base seen express
script one biggest loser medicar part plan enrol loss
januari loss may attribut health transform allianc
optumrx prefer pbm also made signific
stride member live ad januari may prove benefici
compani go forward prospect health pbm
highlight histor progress brand gener prescript sale
prescript volum seen gener product make larg major
prescript dispens us market share compar
prescript volum share brand product declin howev
sale perspect brand product gener maintain market share
sale dollar despit shrink share overal prescript us
histor brand vs gener breakdown prescript
largest pdp plansmembershipmkt shareyr/yr changeytd mark group script plan servic mn mt ne nd wy wellmark ia pa school retir inc cross shield largest pdp pdp barclay servic
histor brand vs gener breakdown sale
weve seen stori drug price spotlight
highlight strong trend gener deflat moder brand
inflat rel prior year drug price continu spotlight recent
us govern look novel approach help lower drug cost
budget discuss addit us govern sped key legisl
recent budget legisl may impact healthcar suppli chain
white hous recent laid budget propos budget
propos larg bypass congress provid sens presid
prioriti possibl action govern could take specif healthcar
broad stroke view govern aim without actual
mechan suggest provid budget provid specif
mechan council econom advisor provid white paper highlight variou
action could taken curb price reduc spend drug
budget govern call new medicaid demonstr author five
state test drug coverag financ reform situat particip state
would determin drug formulari negoti directli manufactur
medicaid contractu oblig receiv best price alreadi
medicar part program budget call allow part plan negoti
manufactur drug encourag util higher valu drug discourag drug
manufactur price rebat strategi govern see increas price
cap pocket spend cap drug
one specif propos call requir medicar part plan appli
substanti portion rebat point sale case hh look
rebat price concess recogn point sale alongsid
govern look exclud manufactur discount calcul
determin fast beneficiari move donut hole
maximum pocket cost catastroph phase budget propos call
increas plan liabil four year decreas medicar
reinsur liabil beneficiari coinsur would decreas
within part program payment drug within program would modifi
discourag manufactur price increas also alter payment hospit
util program
specif polici point laid human servic budget indic hh
would chang first file applic handl approv yet receiv
tent approv receiv non-ftf applic new propos would
kick day exclus period tent approv block ftf applic
yet receiv final approv theoret would bring gener quicker
market outsid exclus period
program hh laid propos includ broad regulatori
author program set enforc standard program particip
requir cover entiti report use program save
ultim host propos budget unclear
propos make law
close doughnut hole one year earlier
pass bipartisan budget act govern made key chang
medicar part program specif brand drug manufactur would requir
provid discount brand drug part beneficiari coverag gap
doughnut hole one year earlier compar prior legisl
would seen come play also major step current
discount brand manufactur current suppli legisl
direct impact pharmaceut suppli chain pressur brand manufactur
could downstream impact suppli chain
council econom advisor white paper februari
prior budget releas council econom advisor put white
paper highlight variou action believ govern could undertak
improv afford reduc cost drug white paper propos
idea larg tie budget releas white hous
medicar part program suggest chang reimburs part
drug paper suggest alter reimburs one tie price
drug current reimburs done averag sale price model
option includ move medicar part coverag medicar part chang
price data report program cite driver cost
program expand beyond origin envis program remedi
cite program includ util precis elig criteria and/or
appoint agenc would set price drug hospit
program would purchas drug
medicar part program suggest allow plan share drug
manufactur discounts/reb patient allow plan manag formulari
negoti better price lower co-pay gener drug patient discourag
formulari plan design speed patient donut hole catastroph
brought pharmaci benefit manag rebat anoth reason high list
price indic pbm gener outsiz profit due market
concentr three player repres market see caus
list price increas turn benefit pbm specif remedi
solut call call polici reduc concentr pbm
market within part suppli chain wholesal pharmaci
beyond aforement area laid remedi drug price
reform biosimilar ensur interchang similar natur gener speed
approv gener drug push reform address cost differenti
drug us vs ou
follow section provid view pharmaci benefit manag
background profit pool
gener view pharmaci benefit manag profit pool broken
six bucket profit gener pbm mail order profit due
arbitrag gener product carri highest margin largest volum
fact pbm take possess inventori therefor extract volum
discount specialti pharmaci also area pbm gener larg amount
profit given special handl servic associ specialti pharmaci
addit per iqvia specialti drug expect grow half drug spend
retail re-bil spread profit earn dispens drug contract retail
network pbm charg plan sponsor higher rate rate pbm
mail order profit gener procur dispens drug pbm
situat pbm contract manufactur purchas drug take
inventori product pbm dispense/mail product member
key gener product gener significantli higher gross profit pbm
particularli pbm abl extract addit discount due move market
share amongst gener manufactur
claim process fee fee receiv per transact basi payor
process member claim brand gener product fee small
gener dollar per claim
specialti profit becom grow compon profit specialti drug
expect grow entir drug market futur per iqvia
given grow import market specialti product expect
clinic programs/oth program wherebi pbm respons manag clinic
program diseas design evalu formulari util analysi etc
perhap one area come scrutini manufactur rebat
driven formulari placement histor pbm kept larg share
brand manufactur rebat declin year particularli medco
began disclos retain rebat howev believ profit tie
rebat previous pbm may offset declin via rebat
discuss rebat price
one hot topic pharmaci benefit manag space back forth
regard drug price rebat rebat provid brand drug
manufactur return gain access formulari pbms/plan sponsor brand
manufactur indic list price drug increas significantli
order off-set rebat demand pbm case retain
pbm profit rebat retain pbm largest pbm indic
retain rebat none pbm publicli report retain rebat howev
figur medco provid amount manufactur rebat retain
seen amount retain declin significantli toward low doubl digit rang
base public commentari publicli trade pbm amount retain rebat
gener rang
beyond publicli disclos rebat amount also provid insight
gross price vs net price discuss origin intent highlight
pbm profit breakdown profit rebil order profit profit process mfr rebat rebat profit breakdown profit rebil order profit profit process mfr rebat rebat manufactur rebat earn medco rebat retain retain growth barclay servic
differenti compani list price epipen
compani actual receiv net revenu went step highlight estim
differ channel player come figur provid breakdown
gross net price epipen highlight variou compon seen employ
gener major save differenti gross net price epipen
compar distributor retail pbm account total differ
gross net price
figur highlight gross net spread brand price
iqvia seen pbm seemingli reduc overal growth net brand price
via rebat past sever year
gross net spread
one key factor pbm industri retent rate compani book
pbm busi gener pbm see rel minim movement book
mfr gross list price epipenwholesal gross margin list priceretail gross margin dispensingpbm/insur retain portion gross rebat gross rebat pass employermfr net epipen pricewholesalerretailerpbm/insureremployermfr net pricemfr gross brand rx price growthnet brand rx price growth barclay servic
busi pbm report high retent rate express script outlier
retent rate past year compani saw roll
unitedhealthcar busi well loss coventri catamaran compani
difficulti retent may also stem difficulti integr medco
compani gener provid updat renew retent rate
begin earn throughout year gener pbm contract three year
durat go long year approxim pbm
book busi grab given year
figur highlight pbm market share go back largest
pbm market share express script second market share
optumrx share help acquisit
catamaran beyond big limit player sizabl scale could
match breadth size big
sell exceed client barclay servic
one expect growth driver move forward growth specialti pharmaci
market figur provid market share breakdown seen health
largest player market follow express script walgreen prime
therapeut combin mail specialti pharmaci oper walgreen
total adjust script script rx part prime total adjust script share total adjust scriptscv script rx part adjust script changecv script rx part adjust script data start adjust retail rx prior period adjust mail rx equival barclay servic
dental/medical/vet distributor manufactur
dental/medical/vet sector distributor manufactur face
price pressur view distributor like see greater disrupt due
threat amazon greater concern product price exampl
on-going litig marketplac alleg dental distributor collud keep price
high boycott dental buy group addit feder trade commiss su
three largest dental distributor anti-competit behaviour among thing
opin possibl outcom litig believ bring
greater spotlight price could alter behaviour industri contrast
manufactur seem insul ftc litig price power may
come similar pressur
dental distributor earn significantli higher margin compar drug distributor
suggest price may high and/or greater threat disrupt
follow figur highlight gross ebit margin dental distributor
drug distributor go back dental distributor averag
higher gross margin compar drug distributor similarli ebit
margin averag higher drug distributor dental distributor
indic ebit margin includ ancillari servic softwar support
carri higher margin given dispar margin leav open
possibl dental distributor could disrupt amazon and/or see
impact on-going litig
healthcar distributor gross ebit margin comparison sector
proprietari survey gaug dental trend sentiment
us europ
conduct proprietari us dental survey practition gaug trend
sentiment us dental market survey gaug patient visit trend price
trend dental consum equip spend trend thought amazon
brief result highlight follow practition expect patient visit rebound
consum purchas trend expect
slightli vs equip spend trend expect
vs price expect higher us consum
product practition expect amazon grow portion consum
gross margin co co margin dental co pharma pharma co barclay servic
figur highlight us dental patient visit expect versu prior year
seen respond expect patient visit rebound compar
gener promis overal spend trend patient
visit tend correl consum spend critic compani
dental space import note howev practition tend optimist
start year moder expect year progress
yr/yr chang us dental patient visit
quarterli basi respond saw slight growth patient visit
period howev period respond expect patient visit
grow may setup strong growth throughout
yr/yr chang quarterli us dental patient visit
consum equip spend trend
figur highlight averag respons expect actual yr/yr chang
consum product spend respond indic expect see growth
consum spend compar see growth lower
growth rate consum spend modestli offset expect growth patient visit
vs vs vs chang patient vs vs chang patient visit barclay servic
yr/yr chang consum product spend
respond expect equip spend rebound compar
respond expect spend increas compar believ
rebound spend may attribut chang sirona equip contract
recal patterson exclus distributor sirona cadcam equip us
patterson sirona declin extend exclus contract henri schein
particip sell sirona cadcam equip us believ practition may
wait see price point respect distributor make
decis equip spend
yr/yr chang dental equip spend
implant procedur us survey practition indic rel steadi growth
compar implant procedur note relev
vs vs vs chang consum vs vs vs chang dental equip spend barclay servic
yr/yr chang dental implant procedur
perhap one critic question ask survey respond
expect relat purchas dental consum product amazon
percent consum purchas amazon indic in-lin
heard consult higher dental distributor
indic importantli beyond respond expect percentag
consum product purchas amazon increas low
doubl digit rang afterward respond expect increas purchas
amazon mid remain earli
seemingli strong interest/trend move procur consum toward
amazon could neg impact dental distributor move forward
 dental consum product expect purchas amazon
vs vs vs chang dental implant purchas consum product amazon barclay servic
addit us dental survey conduct proprietari survey european
practition gaug trend sentiment european dental market survey
gaug patient visit trend price trend dental consum equip spend
trend thought amazon brief result highlight follow
european market patient visit volum expect reacceler vs
consum spend slightli equip spend
vs respond expect price larg higher/unchang
consum purchas consum amazon expect grow less
compar us
figur highlight european dental patient visit expect versu prior
year seen respond expect patient visit rebound compar
absolut percentag increas norm
direct trend posit gener overal spend trend patient visit tend
correl consum spend critic compani dental
space import note howev practition tend optimist
start year moder expect year progress
yr/yr chang european dental patient visit
quarterli basi respond saw growth patient visit
period howev period respond expect patient visit
grow lower seen direct trend
suggest european market could somewhat softer patient visit
vs vs vs chang patient visit barclay servic
yr/yr chang quarterli european dental patient visit
consum equip spend trend
figur highlight averag respons expect actual yr/yr chang
consum product spend respond indic expect see growth
consum spend compar see growth direct
offset somewhat higher patient visit volum expect
yr/yr chang european consum product spend
respond expect equip spend slow compar
respond expect growth equip spend versu seen
view trend make sens practition tend purchas equip
year intern dental show id take place given id
year would expect equip spend moder
vs vs chang patient visit vs vs vs chang purchas consum product barclay servic
yr/yr chang european dental equip spend
implant procedur europ survey practition indic rel steadi growth
compar implant procedur note relev
yr/yr chang european dental implant procedur
perhap one critic question ask survey respond
expect relat purchas consum product amazon
percent consum purchas amazon indic in-lin
heard dental distributor notabl respond expect increas
purchas consum amazon percentag essenti half
respond us indic suggest somewhat loyalti
prime dental distributor and/or amazon presenc yet fulli establish
european market respond truli consid amazon take altogeth
key trend monitor
vs vs vs chang dental equip vs vs vs chang dental implant procedur barclay servic
european consum dental product expect purchas amazon
one measur track get sens dental util job creation
essenti job creat like employ individu go
util dental servic via insur and/or mean addit individu may
dispos incom undergo procedur figur highlight one
month net chang non-farm payrol averag sinc begin januari
job creat month
one month net chang nonfarm payrol
bureau labor statist
one measur track get sens end patient market
consum confid index perfect tracker consum util
give sens busi
consum product expect purchas barclay servic
despit plenti gyrat
fundament driver
manag care industri
chang much
past coupl decad
long track record growth expect continu beyond
track manag organ sector sinc
mani up down past year result econom
commerci employ trend impact membership growth govern
reimburs shift relat differ polit climat medic cost/util
gyrat relat access co-payment/deduct shift good news
fundament driver industri realli chang much past
coupl decad keep simpl boil industri invest thesi
five key variabl outlook medic cost trend pricing/reimburs
outlook commerci govern perspect membership growth
nowaday critic govern program commerci
determin stock perform deploy capit either share
buyback primari use excess cash healthcar polici trend outlook
asid five key variabl also note special attent interest
tax sector right favor view enhanc
ep free cash flow rise interest rate corpor tax reform also
translat greater capit deploy next year sector discuss
five variabl two extra kicker throughout report
variabl trend primarili posit direct next year
longer initi coverag three diversifi manag organ
stock overweight rate unit health group target
annual ep growth next sever year given outlook compani
medicar franchis believ compani track achiev goal also see
compani pois leverag favor secular trend term
price margin corpor tax reduct posit leverag rise interest rate
commerci vs govern medicar part thesi
larger compani sector enjoy period lower volatil
commerci segment unemploy remain low end histor averag
price competit among larger player also fairli steadi lower-risk administr
servic aso agreement major larg employ commerci
membership growth rel stagnant sector view medicar
advantag greatest opportun profit membership growth next
three year believ unit healthcar greatest leverag opportun
among three compani coverag follow
price target unitedhealth group base price-to-earnings ep
estim street believ deserv slight premium
two compani coverag due slightli faster ep growth stem part
optum franchis also rapid medicar growth price target base
price-to-earnings ep estim street compani continu
leverag strength control medic cost embark capit deploy
follow propos merger period final price target
base price-to-earnings ep estim street compani
set stage acceler ep growth pbm save unlock follow
conclus express script contract
spread end membership total manag care coverag
univers continu largest manag care organ
membership million live next closest competitor term size anthem
approxim million live less end
spectrum wellcar approxim million live make roughli
larger term membership
show estim market share product manag care coverag
univers base membership entir manag care coverag univers account
approxim health insur market investor note despit
size public mco signific percentag health insur market
control cross shield plan privat govern entiti
show product mix coverag univers aetna
averag deriv membership aso even healthnet
merger still deriv approxim membership higher growth medicaid
busi line molina wellcar also remain heavili reliant medicaid
membership membership come medicaid
continu deriv membership medicar almost
membership medicar pdp manag care compani
coverag diversif though skew toward aso
membership come aso
start review total medicar elig popul use statist provid
approxim million medicar elig end seen
chart medicar popul grown sinc end
compound-annual-growth-rate approxim per year medicar advantag popul
period growth approxim per year
penetr rate gone medicar popul
go forward expect robust medicar advantag growth age demograph
qualifi greater percentag popul medicar advantag
tradit ff medicar becom better known illustr purpos
shown penetr rate might look like five ten year period
assum fairli constant medicar elig growth trend respect
growth medicar elig could increas beyond histor trend
onward bulk babi boomer start hit cohort believ
republican favor privat medicar could lead reform
significantli increas penetr futur overal believ growth one
biggest area growth mco next year
mechan medicar advantag
medicar advantag plan run independ oper manag organ
contract medicar qualifi medicar advantag plan member must
medicar part part must pay medicar part premium addit
premium plan charg five varieti medicar advantag plan
hmo simplest way think medicar version commerci hmo
product offer employ specif product use gatekeep model
manag plan set network provid contract
discount member choos network provid addit referr need
primari care physician see specialist
ppo rel recent product offer creat medicar modern act
like commerci ppo product member need referr specialist
may use network provid addit fee plan may offer local ppo
licens counti counti region ppo region primarili one
state though rural state combin one region primari differ
local ppo rate standard across counti region plan
standard across region would member-specif risk adjust
significantli local ppo licens region due part fact
region encompass rural urban area high-cost low-cost area creat risk
advers select
ma-pd mapd also creat medicar modern act
first year avail senior product take standard medicar
advantag offer add enhanc drug product product alreadi
drug coverag mapd drug benefit must equival richer part
privat fee servic pff pff administ manag plan use
govern ff network product offer senior broader network
benefit packag rich richer ff sinc plan requir
network enrol member mani plan use pff first step expans
effort decid enrol risk member new market much moot
due chang requir network product basic run
mode point
special need plan snp medicar modern act specif section
creat new type coordin care plan basic special type medicar
advantag health plan creat focu medicar popul
also elig medicaid benefit dual elig special need senior special-
need senior includ institution dual elig
sever disabl chronic condit similarli plan licens one three type
institut tradit chronic-condit
within overal medicar program view medicar advantag import
product line relat analyz stock growth prospect medicar advantag
growth rebound growth growth rate declin
total enrol reach million member end specif
point investor period growth period
us republican govern similar situat current
year period grew compound-annual-growth-rate one highest period growth
ever believ republican govern current place could result polici
except benefici growth would note unlik compound-annual-growth-rate growth
seen replic given base million roughli
four time larger regardless believ current polit environ
highli conduc outsiz growth beyond addit growth seen
age babi boomer
pace medicar enrol pick notabl slower
previou year latest data cover compani grown
enrol compar growth
barclay research estim
medicar advantag annual membership trend growth compani
driver revenu price reimburs
discuss price reimburs trend break two
separ categori commerci trend govern trend
commerci price analysi critic fulli insur live
discuss commerci price mco trend much critic fulli
insur product greater profit risk book mis-pric rel medic
cost trend fulli insur product preval among small mid-siz
employ major larg employ today self-insur
flipsid price overly-competit relat administr fee charg larg
employ self-fund aso arrang
last year aso penetr steadili increas insur mix
trend believ steadili continu futur employ dont want conced
underwrit profit health insur medic cost
continu trend well growth believ shift aso continu
reduc volatil earn capit requir manag care sector
futur certainli posit believ increas aso percentag
mix reduc potenti upsid earn seen appropri manag risk
shown pmpm contribut
plan particip
premium growth rate charg end consumer/employer/pati
shown chart averag annual famili premium reach
employe contribut famili coverag premium grown even faster
annual rate per month total premium employ
bear rest dispar pronounc singl coverag annual
premium grown annual though beneficiari share actual grown
growth total averag annual premium singl famili coverag
growth rate appear modestli differ impact consum wallet
much greater overal inflat run significantli growth health premium
past decad matter consum actual amount money
cost seek care co-pay co-pay
growth beneficiari averag monthli premium singl famili coverag
addit compani estim list result sever nation health care
premium survey relat employ custom base mco annual survey
perform primarili larg independ consult firm among other overal
result suggest premium may increas roughli bp y/i
note barclay estim publish annual barclay benefit manag survey
note bar repres averag sourc
hewitt tower segal kaiser
preliminari trend rate increas expect final rate
increas highlight histori preliminari vs final base rate
 chang due legisl pass subsequ day notic
chart show expect impact polici chang plan payment
rel last three year
medicar star key variabl reimburs
key driver rate mco star rate plan sinc
develop publish annual perform rate pdp plan rate
rang lowest highest base qualiti
plan point refer averag star rate star ma-
pd member plan star rate greater rate
improv time averag star rate increas star star
growth model code data group waiver payment final rate trend chang revenu barclay servic
mapd plan part revenu depend relationship plan bid amount
benchmark plan star rate bid cost plan deliv
tradit benefit standard medicar beneficiari bid
benchmark differ ramif reimburs
bid benchmark revenu equal bid plu portion save
bid benchmark known rebat
rate affect part revenu mapd plan two way
qualiti bonu payment qbp plan receiv qbp benchmark
amount increas qbp percentag base overal star rate
rebat percentag aforement rebat determin rebat
percentag also base overal star rate
chart show qbp rebat percentag
qualiti bonu rebat percentag
new enrol
might expect star rate close follow investor given
import product mani mco mco target mani
beneficiari possibl star better plan order enjoy qbp
award particular star level higher time star rate rise
sector whole increas percentag report plan
star plu categori shown figur
rate time percent plan
highlight commentari public mco star rate
commentari rate
aetna highest percentag membership greater plan among publicly-trad compani
third straight year base project membership growth expect percentag rise rel stabl
medicar advantag membership resid higher plan meaning increas
result indic one health net california inc medicar advantag plan move rate
rate rate year effect rate chang would lower compani parent rate
rate year star star
expect approxim medicar advantag custom four greater plan bonu
payment receiv octob announc rate plan payment year expect
approxim medicar advantag custom four greater plan bonu payment
receiv
addit octob publish updat qualiti rate bonu year show contract rate
star million member rate contract offer repres approxim
medicar advantag membership juli
medicar medicar advantag member enrol plan rate star better
payment year group retire
pleas effort begin yield posit result still work improv qualiti score
posit step forward mean satisfi still contract rate includ
pdp contract imper show improv next year busi rate
good start focus improv star rate across entir medicar busi
medicar reimburs level rel ff
key sourc valu plan abil provid extra benefit base
reimburs level attract senior plan plan abil provid
benefit function effici abil absorb payment level pressur
plan alreadi oper level ff program
chart show medpac estim averag bid would come
ff cost would guess remain lowest competit
level seen sinc program move bid system basic plan price
product discount ff cost addit hmo plan bid
ff cost save increas significantli past year post
implement plan clearli oper level allow
bid safe cost unmanag ff program
medic trend compani
driver medic trend
expect medic cost trend key variabl profit equat alway
top mind investor analyz sector howev project
major mco remain fairli consist major
preced year decad broadli coverag univers expect medic cost trend
roughli y/i averag compar increas full year
commentari mani plan sponsor util persist
low level past year expect tick year also cite
year unusu low pharmaci cost trend may sustain year
believ unit cost primari driver total healthcar cost
anoth data point relat medic cost offic actuari releas
project nation health expenditur februari report
project privat health insur spend averag slowest
major payer report project medicar would see averag annual
growth period medicaid would see averag annual growth
period report cite low enrol growth downward
pressur util growth report cite follow three reason
downward pressur util
lag impact slower incom growth
increas high deduct health plan
lesser extent repeal individu mandat penalti
reason price disciplin
constantli ask explan health insur premium yield
consist hold underli medic cost inflat especi light
competit industri year reason
phenomenon list explan
fewer competitor today
lower interest rate caus need health insur compani price
still opportun shift cost actual member
govern segment opportun continu provid relief manag
organ enrol perspect
larger compani sophist higher local market share
therefor abl project cost trend better opinion
/- low end low end /- /- end /- end end /- barclay servic
past decad state insur depart rais capit requir
make underpr ephemer strategi best
simpl math tell increment premium price valuabl
increment member
believ littl incent cut premium rate grow membership
need increment invest complianc regulatori review lobbi
increas meaning past year
nation health expenditur percent
final analysi overal medic cost trend also look nation health
expenditur percent gpd nation health expenditur increas
continu tick remain
healthcar expenditur reach trillion absolut
basi highest amount ever record roughli billion
percent basi health expenditur stabil rel stabl past
seven year rapidli rise past sever decad
decemb histor nation health expenditur
offic actuari barclay research
believ signific chang health insur benefit recent year reduc
demand certain health servic increas demand other care
expenditur growth outpac wage growth believ caus consum
delay case forgo procedur preval high deduct health plan
increas cost shift consum see consum shift site
care reduc person econom exposur believ trend consum
directli pay healthcar drive consumer healthcar much like
consumer seen retail industri employ also shift focu toward
effect cost-contain strategi result increas regul
healthcar cost employ shift health plan offer toward high
deduct health plan hdhp offer employe well program
kaiser employ survey found employ said well program
nhe growthnh nhe growth growth barclay servic
effect control health care cost follow consum driven health
plan coupl increas hdhp offer increas consum awar
healthcar cost downward trend util like structur chang
firm opinion effect cost-contain among firm offer health benefit
deduct key drive forc within plan design chang year
seen signific increas percentag total payment deduct creat first
dollar coverag therefor everi servic count percentag total cost share
payment deduct increas copay decreas coinsur
payment remain constant plan use co-pay less nomin
tie actual cost servic instead use high deduct coinsur design
actual align incent consum cost healthcar servic
result make consum awar start first dollar spent
coinsur base cost servic provid shown deduct
account half cost share payment friction see healthcar cost
increas beneficiari out-of-pocket expens wage remain fairli stagnant
distribut cost-shar payment type
kaiser famili foundat analysi truven health analyt marketscan commerci claim encount databas
believ type plan employ offer notabl toward higher consum
engag downward effect util kaiser estim
employe enrol indemn type health insur plan
hmo ppo product today convent plan almost non-exist total
wherea high deduct health plan hdhp make market hmo
ppo plan make plan point-of-servic option repres
growth high deduct plan
note hmo health mainten organ ppo prefer provid organ po point servic plan cdhp
medic cost trend remain area focu investor unexpect spike
util possibl commentari compani suggest cost trend remain moder
consist overal manag care compani began year project
increas mlr account unexpect util increas year progress
mani compani reduc guidanc strong exclud
known impact hif moratorium manag care compani
project consist mlr adjust return hif tax
remind hif fee non-deduct tax perspect impact mco
commerci medicar medicaid book busi differ
commerci gener mco abl success pass full cost
fee consum
medicar hif medicar mco de facto rate cut medicar advantag
pay fee fee servic medicar
medicaid net impact medicaid mco
commentari compani mlr
expect consolid midpoint decreas
basi point versu larg reflect impact return health insur fee
asid fee impact outlook flat slightli better
outlook reflect impact intensifi focu drive cost care
across busi maintain disciplin approach price also profit
individu aca-compli busi project improv toward target
margin rang result price particip strategi deploy
improv partial off-set chang mix premium revenu come
govern busi higher consolid averag
 commerci employ book busi expect full year medic cost
trend rang increas full-year trend due
expect increas util pharmaci cost
total commerci book busi expect medic care ratio
rang reflect impact health insur tax
total govern book busi expect medic care ratio
rang
expect consolid hbr
sever item move part includ return hif continu shift mix
marketplac busi effect fide acquisit move part
achiev hbr slightli lower
expect full year medic cost trend rang
increas full-year trend due expect increas util pharmaci
investor day first medic care ratio remov tax expect care ratio
impact somewhat busi mix mostli faster growth govern program
tax creat basi point reduct ratio taken togeth expect
care ratio declin basi point plu minu basi point
continu balanc oper invest product improv return
insur tax add basi point ratio tax flow
earn expect medic care ratio run rang
plu minu basi point midpoint increas much basi point
prior outlook driven sole mechan relat tax rate chang
averag mlr bp y/i due primarili hif
holiday mani compani lower compar
manag care compani initi ci project mlr
bp due primarili return hif off-set sever
flu season higher expect util
compani document barclay research
floor rebat
ppaca pass minimum becam major point focu
signific concern profit would cap long term health insur
three year ago hh releas data first time health insur rebat data
relat commerci oper minimum mlr note much
modest impact coverag univers expect health plan across
unit state paid approxim million rebat consum coverag
univers pay million notic higher plan across
unit state paid million consist coverag univers paid
million total seven compani coverag univers expect pay
million rebat higher last year million rebat
payment good news like signal cost trend ran initi
expect cours best news custom got credit cost
save increas payment million compar
million last year reduc payment million
hh barclay research
changeindividu group changeindividu group changeindividu group changeindividu group net changeindividu group changeindividu group changeindividu group barclay servic
estim largest impact impli impact earn
estim impact commerci health plan coverag univers rang
rebat impact compani mm except per share
hh compani document barclay research
discuss medic cost also worth discuss account trend
prior period reserv develop favor develop alway close watch
investor may repeat come year favor develop repres
differ compani estim claim given period
actual incur word compani estim incur medic
benefit paid claim differ would repres favor
develop follow year
certain amount favor develop posit abnorm high level
favor develop potenti risk factor futur earn futur favor
develop may reoccur extent previou year caus headwind
expect coverag space report favor develop
level past decad compani gotten better better estim
cost factor combin consist conserv reserv practic led
steadier level recent year
impact posit repres cash ep
note larg driven tax rate year result
billion one-tim non-cash defer tax benefit corpor tax reform
end spectrum molina neg affect unfavor
develop repres cash ep
grouplarg grouptotalpremiumsep impactcash barclay servic
pprd impact annual ep million except ep
day claim payabl
reserv qualiti days-in-claim payabl decreas quarter annual
sequenti basi year year basi quarter total day
quarter quarter basi dcp day sequenti day molina
wellcar show increas dcp sequenti y/i basi notabl
y/i decreas aetna day y/i q/q
manag day claim payabl
compani document barclay research
epsprior-year favor develop barclay servic
commerci mlr increas y/i import note three
compani stop report commerci segment mlr
recent restat busi segment commerci mlr longer
compar apples-to-appl basi largest y/i increas seen
lowest y/i increas seen aetna
provid qualit data point regard commerci cost trend
compani longer provid metric
longer break guarante cost make result
incompar peer instead compani report consolid commerci
includ intern busi segment stop-loss product associ
experi rate custom benefit like dental new report
methodolog obfusc core commerci trend make comparison
peer appl orang
continu believ commerci one
import metric measur unitedhealth group last time
explicitli provid measur compani
remind commerci mlr due impact hif moratorium
subsequ fallen due reinstat hif
averag medicar year year note onward
longer provid medicare-specif mlr use consolid
still report medicar includ aetna although
technic govern wellcar show declin medicar
aetna wellcar show increas medicar
note onward consolid
compani spent roughli billion share repurchas dividend
billion total aetna bought back largest amount roughli
billion stock anoth million dividend share
buyback dividend amount roughli total cffo gener
return normal level due termin pend mc merger
remind primari reason declin share repurchas pend
manag care transact aet-hum antm-ci
share repurchas activ million
aetnashar adj ep share repurchas adj ep share repurchas adj ep share repurchas adj ep share repurchas adj ep share repurchas million barclay servic
compani document barclay research
look expect tax reform greatli increas capit deploy activ
industri given widespread consolid health care industri believ
name involv activ except broader view mco
curtail capit deploy activ due pend merger strategi
believ may repeat compani engag
interest rate net invest incom
expect net invest incom invest incom less interest expens portion
aggreg incom continu improv histor low level manag
care compani invest incom tie increas short-term yield
expect increas gener economi improv expect higher
normal interest expens due continu abat leverag level normal
net interest incom percent pre-tax incom group increas
molinashar adj ep share repurchas adj ep share repurchas adj ep share repurchas adj ep share repurchas million barclay servic
net invest incom percent pre-tax incom mm
compani document barclay research
pressur histor lower short-term yield continu abat interest
rate rise improv economi manag care compani essenti health
insur entiti ancillari servic busi mean subject oner
capit requir specif insur requir maintain certain level capit
base amount risk premium write higher qualiti asset
less nomin amount must held fix incom asset rate higher
equiti treasuri rank higher corpor bond etc health
plan typic hold interest-bear asset well excess liabil insur typic tend
maintain larg invest portfolio virtual invest fix incom
secur averag portfolio durat approxim three year estim
secur matur major like reinvest improv rate
notabl earn guidanc compani predic prevail level
interest rate time guidanc roughli three year lag
interest rate movement impact net invest incom secur matur
reinvest current rate highest level seen last
year well level seen prior
 treasuri two-year ytd
interest invest tax ni pre invest tax barclay servic
 two-year t-bill present
yield treasuri bill
coverag univers would realiz averag ep increas invest
yield increas exist invest portfolio would realiz
largest ep impact due compani greater mix ep tie busi line
requir cash reserv convers would least effect
increas yield due compani lower relianc invest incom
percentag earn optum busi compris nearli profit
busi typic requir cash reserv
yieldhmo act level decemb yield yield barclay servic
ep impact increas invest yield mm
note estim base compani guidanc total invest
januari new republican tax reduc statutori corpor tax
rate reduct signific benefit manag care
paid highest tax rate corpor higher tax rate
manag care compani partial due industri fee estim add
averag group averag tax rate manag care
compani compar averag former
statutori rate base guidanc coverag averag tax rate
group roughli exclud molina diversifi name averag
govern name averag chosen break molina due
idiosyncrat issu compani uncertainti revolv around preliminari
guidanc note use tax rate rather refer point due
hif holiday hif tax return tax reform impact result
make appl appl comparison
net tax portion figur net invest mco made extra
fund tax reform estim averag exclud molina
adjust ep guidanc group result tax reform tax reform repres
roughli ep mco point may signific upsid
ep futur increas invest mco abl engag due
tax reform benefit may seen medicaid invest
exampl benefit may seen onward medicar relat invest
exampl overal believ tax reform signific posit manag
care industri invest made due tax reform may provid increas
growth industri beyond
septemb invest impli incom ep ep incremnt ep barclay servic
tax reform impact adjust ep
note molina tax portion may gross net unclear compani report
compani document barclay estim
fee may modestli curtail capit avail deploy
one-year fee break industri fee return
could serv headwind mani compani depend level pass-through
custom tax reform industri suspend could possibl
repeal broader healthcar reform later year order fund
implement healthcar reform particularli expans coverag one
fund mechan implement ppaca mandatori annual insur fee levi
premium gener manag care plan start fee incur
health insur industri total billion look like billion
enrolle includ gross-up word sinc tax non-deduct
effect impact assum gross-up corpor tax rate chang year-bi year
particularli given corpor tax reform
patient protect afford act
show estim total fee impact compani
group percentag total industri fee also show total fee includ
gross-up
guidanc epsnet tax portion ep tax average ex insur yr rate premium growth barclay servic
compani specif impact industri fee thousand
impact industri fee compani specif earn vari base
compani busi portfolio mix growth taxabl revenu vs
instanc impact would rel small given compani higher
exposur self-fund employ account intern busi exempt
health insur fee return opinion moratorium insur fee
particularli benefit medicar advantag plan though plan pass
benefit consum remind sinc member assess much larger
premium pmpm medicar advantag would like take disproportion share
tax per member basi though obvious percentag revenu
perspect estim medicar advantag plan contain approxim
total insur popul countri account roughli total
premium gener addit sinc ff program would assess fee
total barclay servic
fee present long-term problem well year plan bid
reimburs base bid actual cost incur tradit ff
program fee extra cost plan would impact ff program
payment plan would artifici underst
seri signific potenti benefit longer term repeal
afford act manag sector signific net
neg highlight includ medicar reimburs cut minimum profit
cap minimum essenti benefit level industri fee underwrit restrict etc
perceiv benefit expans coverag initi rhetor
republican point curtail medicaid coverag and/or fund see
littl way medicaid expans roll back certainli one believ
exchang live would miss anticip provis
repeal manag industri benefit remind stock trade
trough level price-to-earnings passag
repeal oner provis may improv investor
percept safeti invest manag sector maximum
market recogn potenti benefit republican control white hous
hous rep senat result elect presid
republican control three legisl branch signific chang
signific shift ideolog
tabl illustr key provis implement past year
kaiser barclay research
healthcar exchang major sourc angst manag care coverag
univers sinc becom nonfactor diversifi mco
collect materi reduc footprint side note
molina among public compani still tri grow/maintain exposur
health care exchang health exchang still focal point
investor highlight fourth quarter commentari exchang
mco minor materi exposur exchang
rate reviewreduc market basket updatessmal busi tax creditsdu demonstr programsadult depend coverag condit programminimum commerci marketclos medicar drug coverag gapmedicar independ payment advisori boardaccount organ medicaremedicar advantag rebat bonu paymentsannu fee industrymedicaid bundl payment demonstrationmedicar valu base purchasingreduc medicar payment hospit readmissionsmedicar bundl payment pilot programtax medic devicesco-op plansmedicar dsh payment reductionsmedicaid dsh payment reductionsmedicaid expansionindividu mandat insur exchangesgurante issueno annual limit coverageessenti benefitsestablish rsminimum medicar marketindustri feesmedicar payment hospit acquir infectionsbas planemploy mandat choic compactscadillac tax barclay servic
essenti exchang
end million total individu live million aca-compli littl less
non-aca-compli million aca-compli live littl public exchang
state certain geographi within state
year-end serv million exchang member repres sequenti declin approxim
beneficiari due normal attrit line expect
marketplac busi perform well fourth quarter full year exchang focu remain
provid high-qual afford health care low incom individu began offer exchang product new state
kansa nevada missouri januari million paid exchang member
key demograph member includ age gender financi assist metal tier remain consist
comment made decemb investor day includ modest shift silver bronz brand anticip
upon close fide transact offer exchang product state state last year
essenti exchang
experienc poor marketplac perform demonstr quarterli medic care ratio
fourth quarter full year product run base price
respect marketplac taken signific action improv perform well reduc
overal exposur busi specif implement premium increas averag effect januari
premium increas includ increas absenc feder fund csr subsidi
increas medic cost trend anti-select risk demograph varieti rate factor
price increas along market exit utah wisconsin result substanti lower membership
respons marketplac challeng increas premium rate significantli elimin exposur
uncertainti around csr fund reconcili price full expect would reduc overal
essenti exchang
exchang
go averag premium rate exchang increas
bronz plan silver plan even reveal cagr
show increas one seri outsiz premium
increas becom hallmark public health exchang
note enrole exchang get financi assist
shield headlin premium increas shown said roughli
member qualifi subsidi would feel pinch sharp
increas potenti lead exchang attrit note number
averag certain state see substanti higher lower increas
case increas health insur premium averag far exceed
averag medic cost inflat pile would ventur premium
increas even higher increas repeal individu
mandat place provid even less incent healthi unsubsidis
exchang popul remain exchang cours would lead
deterior risk pool would lead increas premium
averag exchang premium metal level
beyond premium rise well document exodu insur
health exchang coverag point either public health
exchang substanti reduc exposur notabl except centen
molina
counti us public exchang one insur
exchang shown state us insur public
exchang entir state state insur insur sinc
exchang start averag number insur public exchang
drop averag believ could drop
effect repeal individu mandat take effect
total number insur state
note insur group parent compani group affili obtain hh medic loss ratio
public use file supplement addit research
total number insuer barclay servic
strateg intersect pharmaci manag reunit
percept pbm marketplac pbm asset
own oper manag care scale effici
sophist expertis independ pbm abil control pharmaci cost
result independ pbm continu wit market share gain expens
captiv pbm own manag care compani stigma grew among
commerci custom base pbm market carv pharmaci benefit
independ pbm like lead better pharmaci cost trend carv
health benefit administr ultim led market capitul seri
manag care compani decid throw proverbi towel sell either part
pbm asset independ pbm took place roughli year ago larg
mco anthem aetna smaller health plan announc
transact independ pbm wave pbm outsourc
smaller transact occur preced year well involv mco either exit pbm
ownership and/or outsourc independ
unitedhealth group almost single-handedli end stigma
howev grow sophist manag care compani greater
need/desir take hands-on approach control medic cost
buck trend announc around intent bring in-
hous outsourc commerci pbm servic goal build market-
lead pbm asset could success compet busi carved-in
carved-out basi base unh pbm market share
consensu view success achiev pbm goal
success endeavor past five year gone long way toward essenti
elimin aforement stigma marketplac relat captiv pbm
seemingli trigger wave strateg decis pbm manag
market describ greater detail
usher new world order manag pharmaci
discuss section report manag refer
optumrx pbm frequent util real-tim consum touchpoint
entir healthcar system use frequent interact creat whole pictur
member guid peopl clinic appropri medic simultan
provid greater transpar pharmaci cost context overal health
care cost strategi believ optumrx gain pbm market share
 past coupl year market data analyt capabl
connect pharmaci care overal patient care
decemb enter agreement acquir aetna total
transact price bn merger-rel confer call decemb
manag aetna state transact creat lead health
care platform revolution consum healthcar experi healthcar
stakehold state combin compani deliv high-touch connect
consum improv qualiti life drive effici lower cost
care manag went state compani share vision critic role
pharmaci care play deliv qualiti outcom lower overal healthcar cost
togeth compani said plan build entir new healthcar concept
base principl make care easier use afford aetna
consum health engag model cvss reach scale compani plan
util combin clinic expertis enhanc valu tighter integr pharmaci
medic benefit manag manag said combin compani use high-
touch connect becom front door health care consum manag
state combin medicar advantag medicar part asset
two compani new merg entiti abl improv qualiti metric
becom competit fast-grow medicar market
data analyt also variabl cvs/aetna merger accord
relat new compani plan marri physic digit touch point
broader use data analyt inform health care decision-mak integr data
across new enterpris asset use predict analyt
compani said creat target interact patient drive adher
manag see healthcar marketplac evolv value-bas system
import medicar commerci compani plan becom
leader drive adopt value-bas model promot lower-cost site
care ceo aetna particular state confer call transact
potenti medicar medicaid member provid high-touch
interact need navig complex health care system
believ could differ type benefit plan group truli put
financ background reward consum proactiv
manag put number behind manag care/pharmaci save
accord manag combin data analyt enabl new
compani use pharmaci care drive overal health care cost prescript
cost manag demonstr integr medic pharmaci
result increas case manag engag pmpm per
member per month reduct total medic cost averag member chronic
condit save approach pmpm end day manag
note everi basi point aetna reduc medic cost trend result
nearli mn addit underwrit margin aetna custom
implic aetna financi perform well accord compani cost
improv allow aetna reinvest health member drive increas
loyalti retent improv qualiti afford product servic
expand new geographi serv addit member profit top-lin
growth compani expect mn year synergi combin pbm
medicar part oper reduc medic cost shift care lower-cost
set well typic redund corpor function streamlin
also grab back rein pbm servic
underscor view captiv pbm stigma marketplac quit
posit strateg decis creat pbm call ingeniorx start
late simultan conclus pbm outsourc
agreement express script announc strategi
addit serv exist medic member roughli mn prescript
annual new ingeniorx pbm also compet open pbm marketplac
carve-out opportun manag emphas ingeniorx pbm
go market compet free-stand pbm fortun
business/larg local busi core market also discuss
similar compon cvs/aet relat pbm strategi
discuss greater detail
ingeniorx oper end-to-end solut member distinct
competit advantag achiev leverag clinic expertis suit well-b
solut local market focu deep provid relationship align
incent model focus manag overal cost care compon
benefit approach shown figur figur
also look creat solut ensur oper excel relat
partnership health ingeniorx retain control
key pharmaci servic leverag best-in-class oper perform
scale retail presenc clear ingeniorx firmli control
clinic formulari strategi develop member employ experi
account manag sale market retail network strategi
relat price term exist express script well
market rate expect bn annual pharmaci save ingenio
rx run beyond save show primarili
medic cost line
never pull trigger full pbm outsourc option
juli announc pbm partnership agreement independ pbm
catamaran own new pbm agreement minimum
involv shift plain-vanilla prescript claim process function catamaran
initi compon partnership beyond option within
contract term potenti outsourc addit pbm servic catamaran time
howev understand ultim never realli pull trigger
major addit outsourc option past five year thu still
essenti fully-funct pbm in-hous client interfac servic
perspect strateg import emphas analyst meet
describ detail
critic keep pbm in-hous relat value-bas strategi
quit time view pharmaci portion busi critic
effect creat better servic experi clinic outcom individu
increasingli better opportun partner effect health care
profession enabl creat better valu patient evolut toward
value-bas care vbc arrang relat taken step forward
multipl value-bas care program alreadi specialti pharmaci space within
pbm oper orient toward health care profession side
equat point touch/interact individu get pharmaceut
experi integr practition gener much power outcom
manag view number one gap care america still tie
pharmaceut wrong drug wrong dose wrong durat drug therapi
conclus seem share strateg view mani diversifi
mco relat pbm oper
time announc deal catamaran disclos
approxim mn annual adjust prescript rx claim includ
healthspr book busi acquir year prior relat
cigna pbm integr within overal medic benefit book busi compani
rank current pbm penetr mid-high carved-in penetr
exist book increas time pharmaci relationship outpac
growth medic relationship estim may closer mln
adjust rx claim pbm today also adjust retail well
correl fundament stock perform
medicar advantag membership growth price remain one import
variabl overal equat invest thesi
medicar remain driver ep growth larg mco
medicar advantag yield growth rate commerci market recent
year mention believ pois acceler futur given age
demograph polit environ higher growth segment
clearli lost public market ascrib higher multipl medicar
focus name agre market percept long-term view overal
publicly-trad space gener averag revenu medicar
advantag significantli approxim less
ebit margin increas prior year due outsiz earn
growth lower mlr project ebit margin increas due
moder cost trend greater invest incom consist reimburs
 adjust exclud investig cost
ep outlook expect rais game continu
rel first call consensu ep estim fourth quarter result consist
strong perform seen across board eight manag care
organ group seven report earn per share beat consensu
expect date report perspect sinc
compani beat consensu estim approxim time
first call compani report barclay research
invest conclus overweight manag name
put togeth variabl trend primarili posit direct
next year longer initi coverag three diversifi manag
organ stock overweight rate unit health group
target annual ep growth next sever year given outlook
compani medicar franchis believ compani track achiev goal
also see compani pois leverag favor secular trend
term price margin corpor tax reduct posit leverag rise
valuat
run manag care stock valuat histor
norm believ justifi out-performance manag care reflect
combin oper improv polit environ regulatori chang
like tax reform last year manag care trade roughli forward
earn compar averag includ
implement drove stock lowest valuat
level ever would ventur spread stock tighter
averag impli either case mco current trade slight
discount still see meaning upsid potenti cover name
given acceler ep growth
believ relev period manag care group trade
forward earn almost year seri headwind group
trade averag ftm earn year
time commerci name trade earn believ
predict higher post-aca combin favor econom backdrop
believ mco trade premium histor averag
factset thomsonon barclay research
stock rate price target
price target base price-to-earnings ep
street believ deserv slight premium two
compani coverag due slightli faster ep growth stem part
optum franchis also rapid medicar growth price target base
price-to-earnings ep street compani continu
leverag strength control medic cost embark capit deploy
follow propos merger period final price target
base price-to-earnings ep estim street compani
set stage acceler ep growth pbm save unlock follow
conclus express script contract
reuter barclay research estim stock rate ow overweight ew equal weight uw underweight rs rate suspend
price target base multipl ep estim
quarterli annual ep usd
consensu number thomson reuter
set stage new ceo initi overweight
initi coverag overweight rate price
target compani larg execut stewardship ceo
swedish past five year howev retir end
potenti enter new era new ceo gail boudreaux recent
ceo unit healthcar health plan oper unitedhealth group
umbrella decad strong pedigre
execut group commerci government clean hous individu
much invest thesi past coupl year
domin propos merger encourag manag still
execut core oper continu success key product area
nation group market within commerci health plan oper well
medicaid growth respect sinc acquir amerigroup
compani success overhaul medicar advantag oper improv
rate fairli materi biggest disappoint individu
exchang market alon among mco inabl hit profit target
once-promis product area scale exchang exposur
ingenio rx new pbm strategi may unlock sever door
core health plan busi intact recent articul new strategi
improv pharmaci spend custom oct introduc ingenio
rx pbm strategi punchlin expect deliv least bn gross
pharmaci save annual run-rat basi management migrat membership
new pbm platform sharehold key least
benefit accru sharehold pre-tax basi base simpl math could
translat least increment annual ep depend share count
start like hit full run rate save show primarili
medic cost line potenti save believ reach
ep nearli growth report
price target base price-to-earnings ep estim
street compani set stage acceler ep growth
bn pbm save unlock follow conclus express script vendor
contract expect continu execut
group commerci govern health plan push low teen ep growth
stori offer littl bit everyth last sever year
propos mega-merg never came fruition aca-rel exchang opportun
much less fruit initi expect major polit swing factor
sector relev govern plan close half
mix compani pbm contract third parti vendor
somewhat handcuf compani pharmaci cost perspect vs peer
new ceo strong industri pedigre despit compani larg
execut stewardship swedish past five year howev
retir end potenti enter new era new ceo gail
new ceo may usher new anthem
dont normal spend lot time initi report write manag profil
noteworthi compani chang ceo posit particularli
outgo ceo quit success his/her role case outgo ceo
swedish beat consensu earn expect everi year ceo
tenur howev disclos novemb retir replac
gail boudreaux recent ceo unit healthcar medic
insur subsidiari past six year prior uhc boudreaux
held presid role variou cross/ shield plan also part aetna
manag develop program view unitedhealth group seem
busi model mani compani manag care industri tri
emul greater mix healthcar provid servic help support overal manag
care effort client interest see becom greater part
strategi next sever year well
commerci blue success state pillar stori
anthem blue root well-docu year compani
independ license cross shield associ bcbsa key
state show state along approxim market share figur
key market share posit major
anthem approxim commerci market share blue state
also discuss margin profil variou product commerci segment
includ long-term expect larg group small group
individu exchang busi remain quit volatil margin
standpoint commerci enrol trend fairli posit
past sever year compani discuss individu expans via
exchang gener offset small group migrat although
occur order magnitud mani fear around time adopt
public exchang migrat also seemingli led modest amount margin
compress small group/individu portion commerci segment gener
hope membership growth would off-set margin compress relat
exchang seem case exchang busi fallen far
short profit contribut expect larg group commerci busi sens
margin profil inde remain rel consist past year
membership gain seemingli translat oper gain growth key piec
govern busi segment medicar medicaid
end govern busi repres
consolid oper revenu back compani last analyst meet set
goal bn govern revenu repres compound-annual-growth-rate target
expect allow gener approxim bn govern oper
gain repres compound-annual-growth-rate bn may like
end slightli revenu target bn government revenu
base project expect compani exceed govern oper gain
target project bn govern segment
decidedli major driver growth compani revenu earn
past sever year within govern segment dissect medicar
medicaid oper
offer wide rang medicar product meaning presenc
medicar advantag medicar supplement busi well serv lead
administr medicar tradit fee-for-servic program roughli million
beneficiari across state year ago came realiz medicar
advantag franchis particular need overhaul improv growth
profit prospect first ration product portfolio emphas
hmo product ppo product better control medic cost also
recontract mani provid across network increas mix value-bas
arrang includ qualiti measurements/scor moreov made
focal point increas accuraci risk code ensur appropri reimburs
final also focus improv custom servic result key factor
improv rate final
multi-year focu overhaul medicar platform inde paid dividend
relat result today octob disclos
medicar advantag health plan wit improv rate
anthem member enrol plan star greater
worth note
member nation health plan enrol star plan also
achiev statu first time hand plan includ ppo
plan nh ga ky addit recent healthsun america choic
acquisit add approxim member fl anthem fl total
member deal translat antm membership
plan star carrier five plan
respect presenc medicar decad longer
dramat enhanc presenc medicaid acquisit amerigroup back
safe say amerigroup acquisit success given
double-digit medicaid membership growth post annual
compani hit bit speed bump medicaid growth due reimburs
pressur solid govern footprint today see bn worth
increment busi opportun end medicaid
alon opportun relat continu underpenetr manag care
within medicaid still around year ago
opportun relat state special servic popul
histori lesson set stage growth target
begin swedish ceo
swedish becam new ceo march complet
acquisit amerigroup decemb acquisit gave materi
increas govern plan exposur particularli medicaid increas
antm medic membership end end
transact bn price tag amerigroup perceiv mani investor
quit rich translat ep accret expect
ramp accret ultim turn pretti good year
compani grew ep year-over-year adjust
basi switch ep despit wit increas expenditur
gear commenc aca-rel individu exchang
despit end adjust ep compani initi guid
potenti year-over-year initi ep guid least
year last analyst meet still relev execut trend
despit corpor activ conduct formal analyst meet
sinc earli believ still somewhat relev discuss goal
laid analyst march almost exactli one year
swedish took ceo time plan prior
year go-liv around exchang also address oper
challeng compani describ swedish industry-rel
company-specif nevertheless swedish also explain interest join compani
describ under-valued compani incred untap valu
necessit need chang need growth despit success
saw strong growth mission new manag unlock valu unlock
one highlight ad approxim mln new
commerci member come exchang anoth area
membership gain compani also came medicaid via amerigroup
medicaid rfp request propos preced year anoth
mln member eight state includ ca fl ga ky ny tn tx va despit
posit membership result year higher hif insur fee due
non-deduct margin hit due migrat small group busi exchang
compani absorb declin medicar reimburs rate key
factor gener ep growth vs howev ep growth
acceler annual jump point describ next section
analyst meet highlight grew membership mn
member mn mn five-year period
expect grow membership mn member mn mn next five
year expect drive revenu bn
bn growth expect organ grow
bn prior five year membership revenu target
expect drive organ oper incom growth five year period
addit point growth stem strateg
flexibl either accret and/or share buyback ep growth expect
rang annual basi except
due variou cost initi put place drive growth remaind
five year period beyond
report card five-year target establish
compani achiev five-year membership target cite mn
medic member expect stay rel flat
growth commerci nation small group medicar medicaid off-set
exit good portion compani exchang busi year also cite
earlier govern section compani set goal bn govern
revenu repres compound-annual-growth-rate target expect allow
gener approxim bn govern oper gain repres
compound-annual-growth-rate bn compani may like end slightli
revenu target bn government revenu base project
expect compani exceed govern oper gain target project
bn final compani underachiev ep growth target slightli
ep growth primarili high singe-digit period
instead rang howev part dynam fewer share buyback
cure merger process also benefit corpor tax reform lead
ep growth rate like five year ep compound-annual-growth-rate
end high end rang mid-teen
ultim track meet five-year ep compound-annual-growth-rate target well
common theme among publicly-trad mco push greater value-
base contract healthcar provid play ever-mor critic role
financi success govern program also commerci well look back
anthem progress value-bas contract compani disclos bn
spend vbc contract grow per year expect reach
bn end entail roughli provid primari care
physician pcp mn attribut patient also note
hospit contract time value-bas contract recent manag
disclos earn call earli
payment tie value-bas arrang compani expect move
next year given fairli comprehens approach value-bas incent
manag talk past year new ceo clarifi
primari approach enabl provid partnership
seem reson best marketplac today
ingenio rx pbm strategi critic invest thesi
on-going trend industri compani seek manag
pharmaci benefit directli possibl vs outsourc third parti part
holist approach manag healthcar member therebi allow better overal
medic cost save announc ingenio rx octob
take step regain larg portion control pbm need back
script discuss seri strateg compon around new arrang
still bring assist area still dramat differ esrx
ingeniorx oper end-to-end solut member distinct
competit advantag achiev leverag clinic expertis suit well-b
solut local market focu deep provid relationship align
incent model focus manag overal cost care compon
benefit approach shown figur figur
also look creat solut ensur oper excel relat
partnership ingeniorx retain control
key pharmaci servic leverag best-in-class oper perform
scale retail presenc clear ingeniorx firmli
control clinic formulari strategi develop member employ
experi account manag sale market retail network strategi
relat price term exist express script far
market rate expect bn annual pharmaci save ingenio
rx run beyond save show primarili
medic cost line save flow
believ get ep nearli doubl
report
ingeniorx pbm go market compet free-stand pbm
fortun business/larg local busi core market
success whole health approach
compliant
medic
note analysi intern data
anthem guidanc detail provid figur right around time
new ceo announc management note target midpoint
long-term growth project rang prior hif fee headwind come
back mix year corpor tax reform pad ep growth
outlook fairli larg magnitud project ep
repres growth essenti line compani
guidanc least follow ebit declin includ one-tim
item project ebit growth revenu growth flat membership
lower tax share buyback account remain ep growth delta
detail assumpt model ensu page
anthem guidanc histori
 compani miltot medic miloper bilbenefit expens bias low bias low endsg bilsg ratio gainamort pre-tax invest miladj epsgreat epsgreat miltax flowgreat bil ex bil ex treati greater bilshar milnotesassum repo bilassum repo bilassum repo bilassum repo bilbegin remaind yearfor remaind yearfor remaind year compani insur milself-fund miltot medic milcomm membership membership billoc group /- bpsconsolid medic /- bpssg expensesg ratio /- bpsoper gaingreat bilinvest milinterest milamort miladj epsgreat epsgreat flowgreat bilshar milshar bilnotestax reform ep barclay servic
price target base price-to-earnings ep estim
street compani set stage acceler ep growth
bn pbm save unlock follow conclus express script vendor
contract expect continu execut
group commerci govern health plan push low teen ep growth
note price-to-earnings slight discount group reflect slightli lower ep growth
past year rel peer howev upsid scenario suggest
stock could close valuat gap compani demonstr pbm-
relat save fulli track execut standpoint percent
save expect accru sharehold could exceed least rang
provid compani fairli materi amount mln increment
save equal bp save roughli extra increment ep
inc annual membership analysi statist commerci govern medic changen commerci govern medic fund type insur medic chang insur medic membershiplif disabl member dental advantag part part stand-alone pdp separ start chang membershiplif disabl member dental advantag part part stand-alone pdp separ start pmpm statistics insur premium comm gov risk aso medicar medicaid chang insur premium comm gov risk aso medicar medicaid barclay servic
inc oper revenu revenueactualactualactualactualactualactualactualactualprojectedprojectedprojectedprojectedcommerci specialti oper changecommerci specialti oper gain/losscommerci specialti oper amort one-tim invest total compani margincommerci specialti nm nm nm nm nm nm nm nm nm total oper barclay servic
inc annual incom statement mil ep ep ep epscash epscash epscash epscash compon oper invest oper invest medic loss expens ex one-tim addback expens exclud oper incom total oper rate minor interest check fulli dilut ep start dilut share growth expens ex one-tim oper incom per barclay servic
inc annual membership analysi statist commerci govern medic changen commerci govern medic fund type insur medic chang insur medic membershiplif disabl member dental advantag part part stand-alone pdp separ start chang membershiplif disabl member dental advantag part part stand-alone pdp separ start pmpm statistics insur premium comm gov risk aso medicar medicaid chang insur premium comm gov risk aso medicar medicaid barclay servic
inc oper revenu revenueactualactualactualactualprojectedprojectedprojectedprojectedcommerci specialti oper specialti oper gain/losscommerci specialti oper amort one-tim invest total compani margincommerci specialti nm nm nm nm nm nm nm total oper barclay servic
inc annual incom statement mil ep ep ep compon oper invest oper invest medic loss expens ex one-tim addback expens exclud oper incom total oper rate minor interest check fulli dilut ep start dilut share growth expens ex one-tim oper incom per barclay servic
ci quarterli annual ep usd
consensu number thomson reuter
distract stori execut initi overweight
initi coverag overweight rate price target base
price-to-earnings ep estim street compani continu
leverag strength control medic cost embark capit deploy
follow propos merger period potenti merger
look less like even offici govern conclus disallow
nevertheless believ process still materi distract employe
potenti custom like held back earn power compani
potenti well due lower membership growth may
occur otherwis believ pois nice re-acceler
ep growth next year combin sanction lift sens
pois captur market share govern commerci
segment compani also wit robust growth mani non-health care
product line therebi de-risk stori near-term
distinguish leader medic contain
among major mco distinguish compani lowest
report commerci medic cost ratio mcr industri fairli consist
basi shown figur averag approxim point lower
commerci medic cost trend vs major peer sinc base cost
trend equat approxim lower annual medic cost client
believ translat bn medic cost save client vs benchmark
time period key success deliv valu back practition
help achiev better-than-market qualiti perform years-long work
foster relationship paid rank payor
base recent ep out-performance also expect
due part us corpor tax reform ep compound-annual-growth-rate like lead ep
would exceed previous state long-term goal ep
compani rais ep goal
four pillar cigna invest thesi
decad fairli consist deliv target annual ep
growth final result line rang howev one
except host factor seem stock compani first
sanction led financi penalti incur also
prevent market product servic medicar elig base
recent ep out-performance also expect due
part us corpor tax reform ep compound-annual-growth-rate like lead ep
would exceed previous state long-term goal ep
compani rais ep goal
primari compon growth product segment shown figur
 long term revenu margin target product area
mid high singl digit
mid singl digit
mid high singl digit
still focus commerci market growth driver
mani investor believ commerci market fairli stagnant mco due full
penetr like due look narrow len nation account
market inde nation account custom trend favor figur
despit expect grow commerci employ revenu
high-single-digit rang long-term shown figur manag
recent note believ compani space grown
medic membership growth everi singl year decad commerci market
success compris meaning compon growth possibl
within commerci segment abl gener double-digit membership
growth nearli everi singl decad select market compani defin
employ employe membership compound-annual-growth-rate select market sinc
shown figur inde cast slightli wider net commerci
opportun cigna ceo david cordani note employ market
employe rang less innov brought transpar fund
health engag capabl on-sit biometr health coach
innov clinic program despit strong growth market past year
still believ under-penetrated approxim mn member mn
total market plan drive continu growth portion
commerci market on-going specialti innov deepen
relationship note cigna select membership roughli two-third aso stop-loss
guarante cost also attribut success select market
acquisit great-west healthcar due increas capabl scale
also recent highlight commerci growth opportun lower end
region segment name employ employe thu round
opportun combin select post
member compound-annual-growth-rate region segment commerci market shown figur
specialti servic also play key role commerci market success
key focal point analyst meet mid manag note unlik
competitor simpli cross-sel and/or bundl specialti product compani take
integr approach across medic specialti busi behavior
health dental pharmaci compani treat custom holist
total care approach reson particularli well aso client realiz impact
valu deliv bottom line employ overal cycl
retain expand ad relationship tie cigna go deeper strategi
drive greater ebit growth exceed top-lin growth next sever
year inde may sound basic focu afford person
target go deep market driven roughli total custom growth
past year moreov increas penetr rate specialti
servic shown figur led greater client retent time across
entir commerci book busi
specialti servic penetr rate within cigna book busi
less
note penetr rate percentag total medic custom base includ non-med custom
medic trend compani
leader medic contain
part overal corpor strategi focus deep relationship
healthcar deliveri system point differenti quit extens time period
earli adopt better cost contain strategi compani pride
view first commerci health plan usher value-bas care
relationship approxim year ago commerci space part cigna
collabor compani larg physician group relationship
competitor includ larg physician group relationship
well specialist group five disciplin hospit arrang healthcar
deliveri system joint ventur note collect physician relationship span state
key success deliv valu back practition help
achiev better-than-market qualiti perform years-long work foster
relationship paid rank payor provid
satisfact nation health insur top athenahealth payerview
report key measur financi administr transact perform
end day value-bas arrang foundat compani
industry-lead medic cost trend therebi set stage consist mlr/mcr
perform shown figur averag approxim point lower
commerci medic cost rend vs major peer sinc base cost
trend equat approxim lower annual medic cost client
believ translat bn medic cost save client vs benchmark
shown industri section report well model note
compani commerci mcr remain fairli tight band
rang past five year govern mcr
rang surpris given minimum floor mandat
medicar advantag part plan debat time whether
cigna mcr truli lower peer due part percept differ mix
specif seem may slightli smaller book guarante cost
commerci busi vs peer aetna howev sens
talk management industri consult nuanc materi differ
calcul company-wid mlr thu comparison across major
diversifi mco fairli apples-to-appl
annual medic cost trend fairli consist note
quarterli volatil season pattern continu prolifer exampl
commerci mcr tend lowest year due recognit prior period
develop period usual favor actual medic cost
/- low end low end /- /- end /- end end /- barclay servic
end littl lower initi forecast recent period commerci mcr
tend highest calendar year due grow mix high deduct
health plan consumer-direct health plan healthcar spend account hsa
collect tend lead greater use health benefit end
calendar year highest util pocket cost lowest
convers govern mcr tend highest calendar year due
primarili mechan medicar part ma-pd pdp drug benefit part
underwrit respons major pharmaci cost start
year cover cost drug donut hole reach
individu medicar member respons major drug cost
pocket dynam lead swing factor much pt part
mcr result even though pharmaci cost tend equal total medic
cost play primari role total govern mcr swing
percentag point calendar year specif
govern mcr calendar year recent year
final note relat govern industri subject floor
medicar advantag part book busi plan sponsor gener mcr
lower typic pay rebat back make differ
particular compani note govern right
around mark last sever year need make materi
rebat payment rebat key investor focu area relat
shown figur well document stockpil cash
under-lev balanc sheet vs peer due restrict share buyback
 process put debt-to-total capit
context industri closer end management believ mid-
debt cap normal bn liquid today
talk bn capac buyback debt/cap bn capac
debt total capit vs peer
 prioriti part capit deploy strategi
follow unsuccess merger free embark
 strategi potenti use pent-up capit analyst meet june
ci manag expand wish list discuss opportun five
specif area expand global footprint senior footprint broaden
compani pharmaci physician engag capabl broaden retail-bas
capabl expand capabl serv government-bas risk program
believ prematur provid conjectur specif target thu
provid company-specif accretion/dilut analysi particular hypothet
merger note compani fully-funct pbm in-hous
alreadi howev intern bpm servic member could envis
pathway expand pbm offer outsid membership right
acquisit beyond one lesson fail merger
greater clariti take get meaningfully-s mco-to-mco transact
complet term level divestitur may requir well strong
focu qualiti entiti potenti purchas asset
divest satisfi ftc requir despit teach believ vast
 opportun set simpli wide make sort accur predict
may make sens compani model standpoint
instead built decent share repurchas activ order reach ep
estim target compani
lower-than-averag presenc senior market vs diversifi
peer howev success healthspr acquisit five year ago
improv percent revenues/profit medicar low-single-digit
rang mid-teen still peer rang expect
also employ provider-engag model senior market well
suggest senior custom receiv care provid particip
value-bas arrang sinc own healthspr rate within
medicar franchis improv plan star plan
howev sanction cigna medicar market put temporari
black eye otherwis excel acquisit strateg
total capitalizationp averagecigna barclay servic
perspect increas compani leverag fast-grow medicar advantag
market consist profit manner sinc deal close
rel pharmaci manag comment analyst meet
feel quit good current ownership oper captiv pbm
compani proven abil grow success recent year simultan
drive result rel pharmaci trend also overal clinic outcom ci
member juli announc pbm partnership agreement independ
pbm catamaran own unit health group expect gener
approxim ep accret fulli integr new pbm
agreement minimum involv shift plain-vanilla prescript claim process
function cataraman initi compon partnership beyond
option within contract term potenti outsourc addit pbm servic
catamaran time howev understand ultim never realli
pull trigger major addit outsourc option past five
year thu still essenti fully-funct pbm in-hous client
interfac servic perspect re-emphas analyst meet
time announc deal catamaran disclos
approxim mn annual adjust prescript rx claim includ
healthspr book busi acquir year prior relat
cigna pbm integr within overal medic benefit book busi compani
rank current pbm penetr mid-high carved-in penetr
exist book howev percentag increas time manag
comment pharmaci relationship outpac growth compani
medic relationship put togeth estim may closer
mln adjust rx claim today also adjust retail well
critic keep pbm in-hous relat value-bas strategi
quit time view pharmaci portion busi critic
effect creat better servic experi clinic outcom individu
increasingli better opportun partner effect health care
profession enabl creat better valu patient evolut toward
value-bas care vbc arrang relat taken step forward
multipl value-bas care program alreadi specialti pharmaci space within
pbm oper orient toward health care profession side
equat point touch/interact individu get pharmaceut
experi integr practition gener much power outcom
manag view number one gap care america still tie
pharmaceut wrong drug wrong dose wrong durat drug therapi
conclus seem share strateg view mani diversifi
mco relat pbm oper
translat cigna four pillar earn pictur
build bridg earn
cigna character year major rebound follow less-than-stellar
impress ep grew ep gener
note ep y-o-i year ep decad
relat much robust hc segment profit vs y-o-i
note small prior period reserv develop benefit
mn follow much larger benefit mln
recogn year incur mn penalti mainli
relat sanction note addit
financi penalti incur help explain abl
grow healthcar segment profit follow growth
preced segment profit growth vs
allow resum full market product medicare-elig
enrol period full benefit resumpt start occur mainli
beyond compani guid medicar advantag enrol
growth industri averag tie togeth post
impress net incom bn growth expect
bn profit follow pathway core oper growth add
mn profit year-over-year also benefit mn gross
posit impact corpor tax reform partial off-set mn addit
invest back oper specif tie corpor tax windfal
expect global medic custom growth live would
repres growth vs note membership growth
enhanc growth individu exchang member albeit small
base howev individu expect wit magnitud membership
growth instead middl market select custom segment within
 commerci book expect drive membership growth
collect translat ep guidanc revenu growth
revenu growth slightli guidanc rang revenu
growth ep estim high end rang believ
compani continu execut superior medic cost contain
price target base price-to-earnings ep street
compani continu leverag strength control medic cost
embark capit deploy follow conclus propos merger
period upsid target base higher price-to-earnings higher ep
compani abl control medic cost even greater pace expect
downsid target base lower price-to-earnings lower ep compani
less abl sustain industri lead medic cost trend vs peer
 compani earn global supplement benefit disabl life earn medic custom growth compani incom op global supplement benefit disabl life earn medic custom growth advantag member oper guid exclud capit deploymentnot incom end net prior year reserv core gross impact tax add discretionari net impact tax mlnconsolid earn mln barclay servic
 annual revenu model membership statist guarante commerci experience-r commerci medic changeu guarante commerci experience-r commerci medic membershipbehavior changebehavior pmpm actual us guarante commerci experience-r commerci dual changeu guarante commerci experience-r commerci dual global revenu medic non-med order medic non-med order barclay servic
 revenu model non-med busi mil
 revenu model non-med busi supplement benefit invest supplement realiz invest gain loss yr/yr invest supplement disabl life segment invest group disabl life invest group disabl life op mn total op oper changetot op oper barclay servic
 total segment analysi rev profit mil
 total segment analysi rev profit revenu summari segment mn global care supplement disabl life realiz capit compani changeglob care supplement disabl life realiz capit compani revenuesglob care supplement disabl life realiz capit compani net incom mn global care supplement disabl life compani net changeglob care supplement disabl life compani net margin segmentglob care supplement disabl life othernm nm nm nm nm nm nm nm nm nm nm nm total compani net net incom segmentglob care supplement disabl life compani net membership breakdown commer nation us ww medic benefit medic custom excl limit altern hc member growthu commer nation us medic barclay servic
 annual incom statement mil ep ep ep ep ep ep ep invest order oper realiz capit changetot invest order oper realiz capit medic medic loss benefit order pharmaci mail incom ebit includ rate minor non op items/amort net check fulli dilut ep start dilut share growth medic benefit order pharmaci incom ebit includ net per barclay servic
 annual revenu model membership statist guarante commerci experience-r commerci medic changeu guarante commerci experience-r commerci medic membershipbehavior changebehavior pmpm actual us guarante commerci experience-r commerci dual changeu guarante commerci experience-r commerci dual global revenu medic non-med premiumsservic order medic non-med premium -- -- -- -- -- -- -- -- servic order barclay servic
cigna quarterli revenu model non-med busi mil
 revenu model non-med busi supplement benefit invest supplement realiz invest gain invest supplement disabl life segment invest group disabl life invest group disabl life op mn total op oper changetot revenuesnmnmnmnmnmnmnmnmtot op oper barclay servic
cigna quarterli total segment analysi rev profit mil
 total segment analysi rev profit revenu summari segment mn global care supplement disabl life realiz capit compani changeglob care supplement disabl life realiz capit compani revenuesglob care supplement disabl life realiz capit compani net incom mn global care supplement disabl life compani net changeglob care supplement disabl life compani net margin segmentglob care supplement disabl life compani net net incom segmentglob care supplement disabl life compani net membership breakdown commer nation us medic benefit medic custom excl limit hc membership growthu commer nation us medic barclay servic
 annual incom statement mil ep ep ep invest order oper realiz capit changetot invest order oper realiz capit medic medic loss benefit order pharmaci mail incom ebit includ rate minor non op items/amort net check fulli dilut ep start dilut share growth medic benefit order pharmaci incom ebit includ net per barclay servic
quarterli annual ep usd
consensu number thomson reuter
initi coverag overweight rate price
target make top pick first start track
bellweth manag care industri compani long-term success core
commerci medicar medicaid market quit impress recent
unh growth commerci market littl mix due neg
impact individu exchang membership compani larg exit
readili appar industri issu united-execut issu
importantli compani excel growth past coupl year
govern market particularli within compani revamp medicar advantag
offer vastli improv rate key driver revenu
oper profit growth unit healthcar uhc health plan busi
optum franchis differenti vs peer
compani continu execut core health benefit oper end
day unh optum asset realli primari variabl compani industry-
lead long-term ep growth rate note optum account
unh ebit core health benefit busi account optum
ratio may increas seem major compani activ
take place across three optum vertic insight rx
fluke stack leader fundament driver
given oper virtual everi key product categori health benefit
space provid in-depth analysi posit vs peer among
five key fundament driver core health benefit busi short analysi
conclud leader virtual everi categori
price target unitedhealth group base price-to-earnings ep
estim street believ deserv slight premium
two mco coverag due slightli faster ep growth stem part
optum franchis also rapid medicar growth upsid target base
higher price-to-earnings higher ep forecast compani medicar membership
growth optum accret exceed expect downsid target base
lower price-to-earnings lower ep compani underachiev medicar growth
health benefit busi unit healthcar uhc
clariti purpos even though unitedhealth group parent compani stock ticker
refer underli unit healthcar health benefit busi uhc
breviti purpos throughout report given unit uhc health benefit franchis
oper virtual everi key product categori space provid
in-depth analysi uhc posit vs peer among five key fundament
driver core health benefit busi
shown figur begin report unit mn health benefit
member give compani number one posit market share perspect
calcul translat market share within manag care space
shown figur side note next largest competitor overal membership
market share perspect share surprisingli largest
compon uhc membership commerci aso total shown figur
fairli larg portion larg employ market prefer self-fund medic
cost oppos pay underwrit premium health insur compani
fulli insur product drill membership market share product
area worth note commerci membership base slightli larger
unit speak power name brand recognit blue brand
howev commerci aso necessarili growth engin overal
sector anymor govern product mainli medicar medicaid much lower
manag penetr rate within overal enrole base program thu offer
faster industri growth opportun membership perspect nevertheless unit
still market share posit commerci aso
relat govern program unit posit medicar advantag
market share end lead virtual medicare-ded
compani market share unit work hard past sever year
improv medicar rate shown figur unit medicar
advantag busi post organ double-digit membership growth four
past six year expect double-digit membership continu well
overal rank unit fairli high among peer membership despit larg size
one import driver overal invest thesi
note unit also market share posit medicaid trail
unitedcar part group annual unit care uhc revenu model statist group individu incl commerci senior govern medicar supplement uhc medic part chang member statisticsrisk-bas group individu incl -- -- total commerci senior govern medicar supplement uhc medic part statisticspmpm total commerci risk/aso medicar adv/suppl/part changepmpm total commerci risk/aso medicar adv/suppl/part barclay servic
driver revenu unit price reimburs outlook
commerci vs govern discuss membership section report
section matter key compon industri view revenu
growth prospect greater sector primari govern program medicar
medicaid vs commerci market assess dynam figur one
see unit uhc health benefit busi gener total organ
revenu growth annual fastest organ growth rate among
diversifi mco past five year
medicar revenu unit perform better-than-averag vs peer
commerci come back notion uhc medicar advantag
growth essenti drive ship come assess primari driver
overal growth stori note uhc organ growth compound-annual-growth-rate
past five-six year vs compound-annual-growth-rate directli relat unit
improv abil collect bonu reimburs due compani improv
rate medicar advantag plan unit
member enrol plan star better rang
year ago one highest percentag industri among publicly-
trade mco discuss figur
medicaid revenu relat revenu growth unit uhc health benefit oper
also highlight uhc becom one leader medicaid space
grow revenu organ compound-annual-growth-rate past year compani
clearli leverag variou medicaid expans opportun market
past year part health reform good news manag care penetr
rate within overal medicaid popul still remain fairli low well
shown figur figur
unit care benefit revenu guidanc product type
 unitedcar /- bpsunh earn barclay servic
group annual revenu growth trend uhc health benefit oper
noteworthi chang unit health benefit revenu mix
unit torrid growth medicar medicaid past five year note
fairli materi chang revenu mix within unit uhc oper time
period shown figur unit medicaid revenu mix within compani
health benefit busi overal increas total health benefit
revenu expect increas due
project continu double-digit annual growth trend leverag
industri underpenetr major state plan provid in-depth
analysi overal medicaid market futur industri report
also highlight overal medicar revenu also medicar
supplement medicar part within uhc increas total health
benefit revenu expect increas
believ medicar revenu project uhc could prove conserv
model high-singl digit revenu growth franchis vs double-digit
organ growth franchis past year clear expect
unit medicar advantag revenu growth particular outpac compani
total medicar revenu growth particular encourag propos
rate publish last month see figur figur await final
rate april fulli sharpen pencil unit industri revenu
growth prospect next year separ highlight unit also leadership
posit medicar part prescript drug plan busi one key
synergi unit ownership one top largest pbm
compani fold commerci pbm prescript back medco earlier decad
mil actualactualactualactualactualactualprojectedprojectedprojectedprojecteduhc chang yr/yruhc -- enuesuhc uhc compon total uhc barclay servic
shown figur medic cost trend among diversifi mco fairli tightli
bunch cite trend uniqu among major compani
recent year aggreg industri becom much adept
predict manag cost trend unit healthcar forefront value-bas
care vbc arrang action ensur qualiti care happen
appropri set result fewer hospit admiss emerg room visit
still far highest-cost set healthcar provid univers overal unit
spend value-bas care arrang tripl past five year reach bn
medic spend end unit expect number increas bn
unit strength network design clinic manag partial via
optumhealth asset key variabl improv qualiti remov cost instead
one larg nation network decad past compani network
configur advanc stronger relationship patient provid
past five year unit doubl membership premium design tier plan
believ translat lower cost patient use premium care physician
unit healthcar compon trend
upon analyz compon unit medic cost trend expect
shown figur breakdown unit cost util
fairli similar recent year notabl trend break regard
look individu cost categori figur believ potenti sourc upsid
could pharmaci cost brand drug price inflat moder base
industri describ report relat coverag healthcar
distribut sector gener drug price still deflat earli
moreov mani larg pbm recent disclos annual drug trend report
pharmaci cost moder low singl digit sens
could end similar rang base analysi trend far year
lower-than-expect pharmaci cost could alreadi prove sourc earn upsid
year
unit healthcar commerci medic trend categori
end day unit trend among lowest industri
speak volum compani abil control medic cost vs peer
comparison compani across industri shown figur continu
believ compani optum asset major compon favor
comparison provid discuss optum dive final two
key driver unit health benefit busi capit deploy dc health polici
bpsunit commerci medic trend rate utliz increas improv upon qualiti reduct admit bed day partial mitig unit cost drive utliz trend unit cost increas consist prior unit cost specialti pharmaceut innov pipelin barclay servic
optum franchis remain key differenti vs mco
sever year optum forefront ownership healthcar provid
servic supplement unh core healthcar payor busi optum
account approxim unh total ebit view one key event
unh corpor histori full brand major compani health
servic busi ex-health benefit singl optum name
acceler articul invest commun conjunct
compani analyst meet late back manag discuss eight
consum engag support distribut benefit servic health
financi servic oper servic support health care pharmaci
note optumhealth compris first five busi
optuminsight compris next two final optum rx compris
pharmaci benefit manag busi revamp optum highlight
compani analyst meet late novemb manag note
optum bn compani back bn compani end
translat compound annual growth rate time period
despit over-arch view optum manag meet
still get start manag first envis billion market
opportun optum back grown billion today
trillion global ad intern opportun set
busi model show three optum financi model figur
figur figur discuss detail
optum health load provid asset lower set
largest categori asset within optumhealth optumcar healthcar provid
asset overal healthcare-provid ownership strategi care deliveri give optum
primari access point consum compani directli influenc
improv health experi outcom simultan drive valu
healthcar system focu primari care urgent care broader clinic servic
network physician end clinic practic
market howev increas unit complet acquisit
davita medic group dmg bn announc dmg
serv approxim mn patient per year nearli medic clinic featur
primari specialti care also oper urgent-car center six
outpati surgeri center dmg medic group locat ca co fl nv nm
wa dmg asset gener bn revenu oper
margin around break-even low-single-digit past year acquisit
come heel prior activ ambulatori care includ medexpress
surgic affili sca shift valu base care best address
compani focu deliveri care lowest-cost set given unit
balanc sheet expect acquisit provid asset low-cost set continu
within optumhealth given view high likelihood good dmg deal closur
alreadi includ dmg asset optumhealth revenu ebit project
shown figur
optum rx third largest pbm market
combin pacifcar acquisit roll
commerci rx claim medco acquir catamaran
unit own third largest pbm us market market share
total adjust prescript shown figur market share
continu view pharmaci gatekeep key variabl control
medic cost manag refer optumrx pbm frequent util real-
time consum touchpoint entir healthcar system use frequent
interact creat whole pictur member guid peopl clinic
appropri medic simultan provid greater transpar
pharmaci cost context overal health care cost fact optumrx taken
transpar step announc march new pos rebat
program begin consum enrol fulli insur group health plan
drug manufactur provid rebat interest see play
 optum annual revenu model hc provid actualactualactualactualactualactualprojectedprojectedprojectedprojectedavg consum serv mil nana per consum revenu incom revenu changeextern incom revenu revenueextern incom revenu extern rev incom optum extern incom optum extern incom optum extern oper earn barclay servic
role greater pbm market share optum rx time meantim believ
optumrx gain pbm share market data analyt capabl connect
pharmaci care overal patient care continu share gain project high-single-
digit ebit growth optum rx next year shown figur
compani report barclay research
optuminsight includ unh analyt platform focus predict outcom
popul individu lead sourc insight hospit enabl
care provid access data analyt capabl platform also
accolad best popul health manag softwar tool
frost sullivan demand optuminsight advanc data analyt solut
continu grow unit formal present capabl
 optum rx annual enu model rx pbm actualactualactualactualactualactualprojectedprojectedprojectedprojectedadjust rx claim data enu incom changeextern incom enueextern incom extern enu compon incom optumrx extern incom -- -- -- -- -- -- -- -- -- -- total optumrx extern incom optumrx extern oper earn rx depreci amort ebitda per barclay servic
optumiq brand reflect uniqu healthcar intellig embed across
optum franchis unit also enhanc data analyt hospit consult
capabl acquisit advisori board compani former ticker abco
healthcar franchis includ project figur optuminsight
establish leadership posit data analyt provid commun compani
also leader provid data analyt healthcar payor commun well
publicly-trad inovalon virtual pure-play healthcar payor data analyt
consist state see unh optuminsight biggest competitor area
unit state recent payor analyt solut use top us
health plan improv medic claim process qualiti care
without state obviou strong cash flow gener trend hallmark
manag care industri due up-front collect characterist health benefit
premium medic cost paid road unit free cash flow
exceed bn annual similar mani compani space unit
 optuminsight annual enu model hcit actualactualactualactualactualactualprojectedprojectedprojectedprojectedend backlog enu incom enu changeextern incom -- -- -- -- -- -- -- -- -- -- optuminsight enu enueextern incom enu extern incom optuminsight extern incom nmnmnmnmnmnmnmnmnmnmtotal optuminsight extern incom optuminsight extern oper earn barclay servic
also strike nice balanc share buyback primari use free cash flow
compani typic spend bn per year seemingli gear
primarili toward provid asset technolog compani within optumhealth
optuminsight franchis one except unit spent bn
largest compon compris catamaran pbm acquisit buoy
compani optumrx pbm franchis told consist theme unit
activ primarili relat optum day meaningfully-s
acquisit like behind us given compani size market share
compani complet seri publicly-trad manag care acquisit earli
oxford health plan pacificar sierra health servic intend
strengthen unit geograph footprint certain region us ca nv ny ct
particular relat deal compani essenti dormant
 activ last decad believ trend like continu
unit overly-aggress activ compani typic spend bn per
annum share buyback anoth bn earmark annual dividend
shown figur
addit color healthcar provid asset activ
continu build optum platform via organ growth
 manag set target healthcar deliveri establish primari
ambulatori health care market repres least popul
recent acquisit surgic affili earli davita medic
group asset deal still pend go long way toward achiev goal
note alreadi includ davita medic group dmg asset purchas
model even though transact close yet compani current
debt-to-total capit approxim end
end follow catamaran pbm acquisit unit seem
plenti dri powder continu purchas healthcar provid asset choos
 annual sourcesactualactualactualactualactualactualprojectedprojectedprojectedprojectednet comp usesaccount cost payabl cfo investingcapit financingnet chang exchang cash attribut dsic begin end decrease/increas paid paid barclay servic
final variabl unit invest thesi assess dc health polici
landscap overal overal landscap fairli calm moment follow period
greater volatil past coupl year primari risk perspect still
potenti repeal replac fail attempt could stir
pot medicaid like greatest risk factor could impact product area
well variabl believ environ pretti favor
medicar reimburs trend next year polit discuss
public exchang less relev unit compani exit
major exchang
risk perspect compani guid market toward long term ep
growth rate higher peer perceiv risk
time law larg number may make harder maintain
long term growth rate believ risk would like compani pure-
play exampl unit actual wit mid-singl digit ebit declin
overal health benefit busi three consecut year compani
absorb combin poor medicar reimburs health insur fund hif
tax fee aca-rel health exchang start-up cost howev unh overal
optum franchis grew ebit respect three year
therebi allow overal unitedhealth group compani still post
meaning ep growth year mani peer post ep declin
invest conclus valuat
diversifi revenu gener manag care coverag
believ diversif help insul compani earn shock
common health benefit busi due varieti reason reimburs
regulatori polit rhetor busi segment risk etc given current combin
favor industri environ govern reimburs hc
polici perspect coupl robust long-term secular growth trend primari
vertic optum franchis see continu likelihood annual ep
growth achiev model period
initi coverag overweight rate price
target overal risk/reward standpoint see unitedhealth best risk
adjust play fundament manag care sector healthcar servic
broadli due compani diversif coupl lead busi
everi segment price target base price-to-earnings
ep street believ deserv slight premium
two mco coverag due slightli faster ep growth stem part
optum franchis also rapid medicar growth upsid target base
higher price-to-earnings higher ep forecast compani medicar membership
growth optum accret exceed expect downsid target base
lower price-to-earnings lower ep compani underachiev medicar growth
 compani unit care part bn employ targetsoptum consum miloptuminsight biloptumrx adj bnebit target medic bpsoper cost mil ebit reduct due premium chang due taxminor mil yr/yrdebt/tot cap lt ltmarket rate barclay servic
 annual segment analysi analysisactualactualactualactualactualactualprojectedprojectedprojectedprojectedcompani revenu summaryunit care uhc optumrx intern optum intern optuminsight intern changeunit care uhc optumrx intern optum intern optuminsight intern total revenueunit care uhc optumrx intern optum intern optuminsight intern ebit summaryunit care uhc optumrx intern optum intern optuminsight intern margin summaryunit care uhc optumrx intern optum intern optuminsight intern yr/yr changeunit optumrx intern optum intern optuminsight intern total ebit segmentunit care uhc optumrx intern optum intern optuminsight intern barclay servic
 annual incom statement compani compani compani medic loss ratio product product profit total cost ex-stock comp expens includ incom intang amort pre-tax rate minor interest net incom exclud check ep fulli dilut share barclay servic
 quarterli segment analysi analysisactualactualactualactualprojectedprojectedprojectedprojectedunit care uhc optumrx intern optum intern optuminsight intern changeunit care uhc optumrx intern optum intern optuminsight intern total revenueunit care uhc optumrx intern optum intern optuminsight intern ebit summaryunit care uhc optumrx intern optum intern optuminsight intern margin summaryunit care uhc optumrx intern optum intern optuminsight intern yr/yr changeunit optumrx intern optum intern optuminsight intern total ebit segmentunit care uhc optumrx intern optum intern optuminsight intern barclay servic
 quarterli incom statement compani compani compani medic loss ratio product product profit total cost ex-stock comp expens includ incom intang amort pre-tax rate minor interest net incom exclud check ep fulli dilut share barclay servic
corp quarterli annual ep usd
consensu number thomson reuter
initi equal weight rate
initi coverag equal weight rate price
target base price-to-earnings calendar ep estim street
equat ebitda sever materi news item
past sever month affect invest thesi posit includ gener
product ration one larg gener manufactur corpor tax reform
late rel strong start brand drug price flipsid
trump administr made recent comment aggress go brand drug
price still seemingli continu unfavor gener drug
price deflat headwind relat expens mismatch
scale walgreens/rit aid asset purchas wall
street journal began report walgreen talk buy rest
alreadi current own share revers feb
news articl suggest near-term merger less like
gener price deflat remain thorn side
one biggest headwind past coupl year persist gener
deflat trend much wors histor averag latest data point
iqvia indic adjust gener price per prescript continu declin
recent data point indic gener price decemb
seemingli respit acceler deflationari headwind despit commentari
gener manufactur product ration would occur may help
price addit fda continu approv older gener product like
keep pressur gener price
share quit volatil recent month receiv boost recent
week due broad press articl februari suggest walgreen talk
buy remain current howev articl februari
revers given fundament trend discuss believ price-to-earnings
ep estim appropri repres slight premium
peer due larger specialti distribut footprint coupl
long-term acquisit option altogeth see stock fairli valu
point thu initi coverag equal weight rate
stock low back gener manufactur commentari
suggest product ration may curtail deflat
gener product
addit news articl indic walgreen earli discuss acquir
remain portion coupl rel in-lin
brand inflat addit volum rite aid stock react favour
howev junctur believ good news price minim
addit tailwind propel stock buy side gener deflat continu trend
low-double-digit rang slightli wors compani guidanc may abat
year addit fewer new first time gener launch horizon could
bolster ep growth particularli enter given major core drug
distribut oper profit roughli two-third gener gener product
portfolio collect lead us equal weight rate
news articl suggest look acquir
februari wall street journal indic walgreen earli
discuss acquir remain portion equiti own
accord articl compani began talk week prior februari
articl talk earli stage offer and/or deal tabl prior
deal articl market capit enterpris valu
alreadi own equiti warrant issu conjunct
wbad like make deal palat overal cost perspect
day articl abc share vs flat unclear
price would will purchas base share price
time would suggest compani would purchas ep
ev/ebitda aforement valuat look rel low compar
histor averag includ contribut would elimin
abc/wba combin ep ebitda metric need adjust
howev februari news articl suggest talk
walgreen may end without agreement cnbc walgreen
deal talk cool take-over look unlik
recal repres revenu addit take
relat revenu due wba acquisit asset rite aid ebitda/ebit
contribut never disclos believ ebit margin corpor
averag may lower base compani commentari
view two compani could eventu come togeth given wba stake
time alway uncertain perfectli clear benefit would
beyond financi accret take togeth would good news
sharehold ever occur
gener drug price remain problem drug distributor
note industri section report price gener front remain
sore spot drug distribut industri expect gener deflat run
rang given approxim two-third drug distributor profit core
oper deriv gener drug declin price gener continu
hinder profit manag believ trough eventu reach
yet materi base industri data analyz gener
manufactur teva other announc plan ration portion
 gener product portfolio well gener manufactur capac
remain unclear materi enough stem declin gener price
entir industri
brand price front certain percentag brand profit tie level
inflat manag current expect brand inflat lower
prior year major brand profit fee servic basi level
brand inflat play role profit like smaller piec overal profit
manag look restructur contract brand drug price trend earli
rather robust brand product see price increas averag
trend recent year term number product see price
increas januari variabl profit tie brand product smaller
nonetheless posit drug distributor separ
start see benefit rite aid busi walgreen acquir store
first half help allevi expens mismatch
compani see
scaled-down rite aid asset purchas walgreen still benefici
abc largest custom walgreen acquir rite aid store store
eventu roll-on book busi remind invest upgrad
build new distribut center support full rite aid acquisit unfortun
walgreen eventu settl rite aid light transact compani
would acquir less half rite aid smaller store benefit lower
previous envis extra busi still benefici nonetheless
abc guidanc contempl roll-on acquir rite aid store abc
guidanc assum complet store acquisit compani
benefit rite aid larg event full quarter
recal mckesson current drug distributor indic repres
revenu believ like bring increment rev
full year basi believ new rite aid store add point
revenu growth base believ busi contribut ep
assum ebit margin sale recal store roll onto walgreen book
stagger period thu lower contribut period onboard
store progress somewhat faster envis spring
timelin april/may view set march-end timelin base
manag commentari may provid modest increment upsid
addit benefit goe all-in wbad
smaller deal walgreen somewhat disappoint
option join wbad joint ventur provid ancillari benefit
specif rite aid compani join wbad store
transfer walgreen occur part agreement brand product
requir sourc option join wbad expir may
contract expir march given dynam could still
stand benefit brand product side albeit low margin like becom
distributor gener product rite aid opportun put variou
rfp decid exercis wbad option specif rite aid remain
non-committ whether would join wbad like entertain
possibl bid cardin health addit possibl join
albertson process acquir remain store current albertson
serv contract theoret could chang hand
beyond possibl rite aid join wbad could see addit ancillari
benefit recent join express script wbad jv recal compani
announc may compani would join wbad base
discuss express script manag esrx indic compani
recent harmon contract see benefit believ
could flow parti jv well
remind walgreen largest custom repres sale
also particip wbad joint ventur entiti negoti acquisit price
gener manufactur relationship extend may run
part relationship extens compani made certain concess
work capit agreement made addit invest infrastructur
relat pend acquisit walgreen addit walgreen gain
warrant tie abc particip origin wbad contract
exercis current own share
benefit variou partnership minor stake joint ventur walgreen
conduct variou particip healthcar suppli channel took minor
stake pharmerica kkr major stake holder contract lost due
contract disput expect enter wbad fold presum see
return contact cardin health contract contract end date
june unclear contract chang hand prior contact expir
afterward either case benefit extent
diplomat contract renew
current contract diplomat pharmaci dplo set end
septemb diplomat spoken contract renew expect
improv price possibl switch vendor order achiev better purchas
econom perspect assum dplo full cog run
would suggest full year revenu grab margin
compress via renew loss contract would impact would impact
manag quantifi tax benefit tax reform compani earn
call compani expect new effect tax rate rang
would equat full year ep benefit part compani
updat compani also rais free cash flow expect
manag indic tax rate expect come
even bp
updat guidanc call compani maintain
revenu growth view oper expens updat reflect
hd smith acquisit see oper expens growth
distribut profit growth lower profit growth
lower total compani oper profit growth lower
lower profit outlook due hd smith acquisit rather
due voluntari closur pharmedium facil memphi carri
pharmedium volum addit compani lash group also see
headwind compani full year tax rate expect compar
view previous ep expect
chang guidanc compon
expect better
look beyond period period seemingli set solid growth year
compani busi on-line much better
revenue/expens match compar addit invest
compani made begin dissip duplic system begin roll-
manag quantifi expect level oper expens growth
manag note expect return normal level oper
expens growth view suggest oper expens growth rang
possibl compar oper expens growth expect
hd smith acquisit compani also lap pharmedium
facil closur relat expens compani also take pharmerica
may lose diplomat contract contract lower margin rate ultim
critic factor gener price
novemb announc acquisit smith independ
wholesal cash deal close januari expect deal
slightli accret ep achiev full run rate synergi ep
accret deal includ smith subsidiari triplefin
pharmaceut brand support provid aret pharmaci pharmaci servic
administr organ issu new long-term debt fund acquisit
time acquisit announc compani updat certain key compon
guidanc compani see revenu growth
distribut servic profit growth total oper profit growth
chang ep
continu see headwind relat pharmedium busi
compani voluntari close memphi facil contain capac
autom four pharmedium facil closur done ensur
facil full complianc fda regul new compound
polici closur caus major headwind relat new
guidanc perhap somewhat promis plant closur voluntari closur rather
forc closur perspect prudent decis given
possibl mandatori closur facil may kept facil close much
longer addit could reput risk given voluntari
closur management believ abl get facil back run
although higher expens relat provid nice benefit
compani lap drag result
pharmedium busi significantli higher margin compar core
busi base pharmedium six month period end june
compani adjust ebitda margin ebit margin
margin significantli higher core margin
time acquisit expect deal accret ep
gener synergi pharmedium provid outsourc
compound steril prepar acut care hospit
chang oper structur
toward end period manag reorgan oper structur
compani compani report singl pharmaceut distribut servic
segment combin legaci amerisourcebergen drug corpor abdc
amerisourcebergen specialti group absg busi togeth one umbrella
addit consult servic busi consolid new distribut
servic segment term come compani move third-parti
logist busi distribut servic segment world courier oper
segment altogeth seem may somewhat less disclosur
variou part busi view slight neg
share quit volatil recent month receiv boost recent
week due specul walgreen talk buy remain
current sever materi news item past
sever month critic fundament well first gener product
ration larg gener manufactur corpor tax reform posit
develop late well brand drug price rel strong start
flipsid trump administr made recent comment aggress go
brand drug price still seemingli continu
unfavor gener drug price deflat compani
headwind relat expens mismatch scale walgreens/rit aid asset
purchas given fundament trend discuss believ price-to-earnings
ep appropri repres slight premium peer
due larger specialti distribut footprint coupl
acquisit option altogeth see stock fairli valu point thu
initi coverag equal weight rate
 servic profit profit profit marginsdown bpstax changeshar repurchaseoffset dilutionoffset dilutionoffset milgener new genericscontribut new genericscontribut new genericssimilar prior yearsimilar prior yearsimilar prior yearno signific contribut biosimsno signific contribut biosimsno signific contribut biosimshd smith acquisit includedhd smith acquisit includ barclay servic
 annual revenu model mil abcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmtotal ebit barclay servic
 annual incom statement distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay servic
 annual revenu model mil abcabcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay servic
 quarterli incom statement mil ep ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay servic
cardin quarterli annual ep usd
consensu number thomson reuter
initi equal weight rate
initi equal weight rate pt base
price-to-earnings ep estim street equat ebitda
equal weight rate predic key factor continu see gener
gener
manufactur may enough perceiv amazon threat
drug distribut oper compani ebit see amazon potenti
disrupt forc cah medic oper ebit albeit
distribut portion medic vs manufactur asset compani medic
busi seemingli take share competitor owen minor distribut
portion oper hamper somewhat medic manufactur op
suppli issu rise commod inflat key cost input latex exam glove
etc acquisit medtron patient recoveri busi look track thu far
though still earli cordi busi unexpect issu
specif intern portion detail next page
cardin discuss gener price slightli differ fashion peer
manag refer sell-sid price relat mid-single-digit deflat guidanc
assum gross margin gener drug distributor calcul
cardin guidanc equat buy-sid gener deflat howev
current industri data suggest buy-sid deflat low-double-digit could
lead overal profit squeez cardin current embed
guidanc word compani sell-sid price may deflat mid-
singl digit gener manufactur conduct product ration
stabil gener price may enough save overal industri
current trade lower end histor price-to-earnings valuat rang
surfac may make stock look somewhat compel howev compani lever
ebitda relat recent acquisit valuat slightli
midpoint histor ev/ebitda rang nearli current ebitda
estim view investor less like re-rat multipl higher due
continu gener price amazon overhang initi equal weight rate
similar drug distributor continu see high singl digit level gener
deflat diminish first time new gener launch would bolster cah profit
perhap importantli specter amazon loom larger cardin due
compani medic distribut busi focus larg hospit recal amazon
variou procur pilot health system hospit plan disrupt
current supplier cardin owen minor may take time amazon
take materi market share nonetheless creat headlin risk
acquisit medtron patient recoveri busi expect quit accret
cardin may still partial off-set host discret item soft
compani core drug distribut oper moreov cordi oper seemingli
pressur given factor impact medic busi continu gener
deflat combin recent leverag balanc sheet relat recent
deal initi equal weight rate share
januari mike kaufmann assum posit ceo cardin health
replac georg barrett remain execut chairman board
novemb gregori kenni cardin health lead independ director take
role non-execut chairman time kaufmann spent year firm
serv chief financi offic well overse global sourc
medic segment jorg gomez take new
cfo previous serv svp cfo cardin health medic segment
cfo segment recent donald casey jr ceo
medic segment announc ceo jon giacomin
ceo segment would becom ceo medic segment
question remain whether bottom reach gener deflat
cardin assumpt mid-singl digit deflat gener drug price
slightli lower deflat assumpt one main competitor
deflat howev specif defin gener deflat declin
sell side price brand drug price assumpt inflat
line competitor expect still slightli higher
red oak establish juli -base gener pharmaceut sourc
ventur initi year contract jv negoti gener pharmaceut
suppli contract behalf compani allow benefit lower gener
cost competitor also establish sourc jv
walgreen claruson date
red oak continu perform well exceed manag intern expect
see continu futur potenti upsid help mitig effect
gener deflat remind compani current pay
part jv agreement
smaller specialti footprint compar competitor
compani sale specialti busi manag note
includ specialti drug fill via normal distribut busi would add
cardin exposur medic
devic distribut uniqu
compar two largest
competitor make
somewhat less vulner
medic distribut manufactur segment
cardin close previous announc acquisit medtron patient recoveri
busi billion juli deal bring manufactur facil highli
complementari product portfolio cardin product categori includ argyl
curiti devon kangaroo kendal monoject acquisit enhanc cardin
exist portfolio increas scale manufactur sourc build geograph
reach expand channel reach
cardin expect achiev million annual oper synergi end
expect accret inclus
inventori step-up cost expect first quarter follow close deal
busi bring revenu base ltm end
greater revenu gener us deal fund
new debt cardin expect leverag slightli greater adj debt/ebitda
end
specul amazon enter healthcar space continu overhang
healthcar suppli chain regulatori concern may signific enough prevent
enter pbm pharmaceut distribut space lower end medic
devic seemingli pose barrier entri amazon alreadi compet
extent space amazon busi alreadi offer varieti medic suppli
includ infus pump cathet iv bag sutur forcep hospit bed scalpel
lab item howev mani low cost item packag bundl larger
contract could inhibit amazon abil gain share high volum custom
cardin exposur medic devic distribut uniqu compar two largest
competitor make somewhat less suscept erod profit amazon make
signific move space specif compani manufactur host
product competitor less manufactur capabl nevertheless cardin
penal somewhat due compani higher exposur medic space rel
updat outlook follow result includ benefit tax
reform slight chang busi assumpt adjust ep
expect compani new effect tax rate
assumpt compar origin view segment perspect
segment contribut less ep due earli close
cardin china divest previous compani assum full year
contribut within medic segment core medic segment expect flat
driven weak cordi
recal compani initi outlook provid april compani
announc acquisit medtron patient busi time compani
cite variou headwind despit expect benefit least ep
busi acquisit specif manag expect least
ep headwind variou discret item item call manag
posit discret tax item wont repeat higher funding/accru
employe incent compens increment invest specif area
long-term strateg posit
compani multi-year
pharmaceut inform system refresh manag character larg portion
ep relat tax reserv compani would also face
loss veteran affair contract medic segment impact larg began
beyond updat compani provid addit updat call
cite addit ep impact specif custom invest
specif invest yet conduct manag expect occur
final quarter fiscal year
addit guidanc compani also provid view
manag target ep least time guidanc tax
reform contempl compani outlook cardin health china
includ ep target base midpoint initi guidanc
impli ep growth rate assum rate hold true
suggest ep take account tax reform howev manag
reiter view recent earn call cite move part
overal busi earli provid addit detail view
factor consid
ep target affirm posit path
compani see neutral impact pharmaceut system refresh
impact compani could see volum greater
particip medicar part network pharmaceut ebit margin may also improv
year/year basi easi comp medic segment could also see ebit margin
near mark given inventori step charg expect
presum addit compani adjust sg expens
cordi full year contribut busi alongsid synergi
compani would also lap impact va contract loss
variabl could impact growth cordi busi expect
flat drug price anoth factor could weigh overal
busi remain seen price stabil longer declin
year/year basi and/or eas declin seen cardin also expens
tie custom invest yet occur manag expect
completed/occur could bleed could weigh ep growth
report result best street expect compani report ep
well street view lower tax rate quarter
contribut ep core beat came better expect perform
within segment quarter also saw benefit
busi quarter came expect off-set weak
cordi medic busi medic segment absorb anoth million
inventori fair valu step-up expens relat patient recoveri busi
last quarter expect incur inventori step-up charg forese
futur notabl exclud inventori step-up charg ebit margin
medic segment would almost guid
compani out-performance segment driven red oak
sourc jv accord manag brand gener price in-lin
compani expect cordi issu revenu expens side
global suppli chain ineffici relat manufactur plant closur
elev sg ou busi tax expect lower
full year enjoy full year corpor tax reform benefit
receiv partial year benefit could trickl run rate due
elimin certain us tax deduct occur chang fiscal year
pt base price-to-earnings ep estim street
equat ebitda equal weight rate predic key factor
continu see gener price challeng throughout despit ration
gener manufactur may enough perceiv amazon
threat drug distribut oper compani ebit see amazon
potenti disrupt forc cah medic oper ebit albeit
distribut portion medic vs manufactur asset compani medic
busi seemingli take share competitor owen minor distribut
portion oper hamper somewhat medic manufactur op
suppli issu rise commod inflat key cost input latex exam
glove acquisit medtron patient recoveri busi look track thu
far though still earli cordi busi unexpect issu
specif intern portion busi
current trade lower end histor price-to-earnings valuat rang
surfac may make stock look somewhat compel howev compani lever
ebitda relat recent acquisit valuat slightli
midpoint histor ev/ebitda rang nearli current ebitda
estim view investor less like re-rat multipl higher due
continu gener price amazon overhang initi equal weight rate
digit percentag growth vs mid-singl digit percentag growth vs mid-singl digit percentag growth vs mid-singl digit percentag growth vs non-gaap effect tax expens dilut eps-flat mid-singl digit ep excl china dilut key ep headwind discret tax law benefit discret itemsm a-rel intang patient recoveri busi pharma segmentrevenu growth-low mid singl digit growth-low mid singl digit growth-low mid singl digit growth-low mid singl digit growthprofit ebit growthful year ebit high singl digits-down low doubl digits-down low doubl digits-down low doubl digits-down low doubl digitsgener pricing-mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid -mid-singl digit deflat sell-sid brand inflat full fiscal inflat full fiscal inflat full fiscal inflat full fiscal yeari/t investments-increment expens increas y-o-y-increment expens increas y-o-y-increment expens increas y-o-y-increment expens increas y-o-ygener launch contribution-new launch benefit much lower y-o-y-new launch benefit much lower y-o-y-new launch benefit much lower y-o-y-new launch benefit much lower y-o-yr oak contribution-less benefit y-o-y-less benefit y-o-y-less benefit y-o-y-less benefit y-o-yspecialti contribution-double-digit revenue ebit growth-double-digit revenue ebit growth-double-digit revenue ebit growth-double-digit revenue ebit growth china sale close guid assum full-yr contributionep guid assum full-yr contributionep guid assum full-yr contribution-ep lower earli sale closemed segmentrev growthhigh-teen revenue growthhigh-teen revenue growthhigh-teen revenue growthhigh-teen revenue growthebit growthstrong double-digit growth w/ strong double-digit ebit growthstrong double-digit ebit growthstrong double-digit ebit growth patient recoveri accret inventori step-up inventori step-up inventori step-up inventori step-up medic busi ex deal solid growth core medic ex- solid growth core medic ex- solid growth core medic ex- -flat-to-down due cordis/glovesebit ebit margin exce ebit margin exce ebit margin exce ebit margin exce affair va med contractsignificantli y-o-i start y-o-i start y-o-i start y-o-i start devic tax notesno reinstat medic devic taxno reinstat medic devic taxno reinstat medic devic taxno reinstat medic devic tax barclay servic
 annual revenu model mil cahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin annual oper profit mil cahcahcahoper profit ebit ebit ebit ebit barclay servic
 annual incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay servic
 quarterli revenu model mil cahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahoper profit ebit ebit ebit ebit barclay servic
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay servic
quarterli annual ep usd
consensu number thomson reuter
initi equal weight rate
initi equal weight rate price target base
price-to-earnings ep estim street equat
ebitda equal weight rate predic key factor continu see
gener price challeng throughout despit gener manufactur
ration believ amazon threat compani core
drug distribut oper amazon could disruptor within mck medic
distribut segment gear toward physician practic recent physician
survey suggest physician practic open util product amazon beyond
primari distributor specif physician respond indic purchas
consum product via amazon expect grow mid-teen rang
next year drug price rhetor within brand gener market continu
take toll industri could neg impact distributor
gener price deflat overhang
explicitli provid guidanc gener price trend compani
immun deflationari trend overal gener drug market
compani joint ventur via claruson help improv gross profit
within distribut busi elev level gener deflat may squeez
overal profit dollar claruson deflat persist throughout
recent data iqvia suggest gener price buy-sid y/i
decemb believ like persist despit gener manufactur
valuat pt base ep
continu trade pe valuat low end histor rang
compani face variou headwind form drug price concern brand
gener product elev level gener deflat concern regard amazon
within drug distribut market addit compani medical/surg busi
gear toward physician offic also suscept amazon similar natur
cah product given factor believ stock stall near term
initi equal weight rate pt base ep
drug price continu sore spot drug distributor note industri
section report explicitli guid gener deflat assumpt
compani expect nomin contribut gener howev expect
gener deflat continu headwind compani given high singl digit
deflat level gener product gross profit impact gener deflat
somewhat mask compani jv relationship via claruson
compani lower distribut ebit margin assumpt origin guidanc
bp
brand inflat perspect compani expect brand inflat mid-singl
digit rang brand inflat trend compani
import note howev struck new contract brand manufactur
seemingli shift cadenc brand econom and/or reduc variabl tie
brand inflat given dynam remain unclear much brand inflat play
role overal compani profit
expand relationship format claruson
contract entiti gener product
recal alreadi distribut brand product claruson entiti
book entireti revenu profit book howev
compani seemingli may major share entiti rather control
entiti govern right benefit via gross profit line due better
contract term base understand entiti pay fee
claruson entiti negoti consolid buy power similar
natur wbad jv walmart profit share fee incom claruson deduct
via minor interest expens line
difficult ascertain actual dollar benefit etc jv clearli see
gross margin distribut solut busi improv somewhat
recent quarter import note compani move certain busi
distribut solut segment covermym relayhealth carri
significantli higher margin core drug distribut busi nevertheless
benefit deriv claruson
manag previous quantifi expect rite aid contribut
compani expect total rite aid contribut revenu ep
note manag indic guidanc alreadi assum impact
rite aid roll although expressli quantifi perhap one posit
current deal rite aid walgreen smaller
origin anticip recal walgreen acquir eventu settl
scale acquisit asset store total store rad
store leav half store remain howev
option join wbad jv store transfer
walgreen may put remaind store risk move wbad
mck/ contract run march wbad jv option avail
may assum chang busi contract expir
theoret keep remaind busi howev indic
decid move wbad would benefici may seek exit
contract earlier asid risk contract loss wbad would like
make superior bid order retain busi would like reduc
profit remain busi stay mck hand
take altogeth like see profit pressur relat one
form anoth term estim impact estim roll-off impact
neglig look ahead current estim roll-off remain
store headwind translat ep
albertson deal may creat addit uncertainti
februari announc albertson would acquir remain store
albertson alreadi custom current contract run april
contract run march repres revenu
assum full store contribut cut nearli half store roll
base detail rite aid/albertson merger materi remain rite
aid prescript per year ltm current albertson pharmaci
repres sale although expect profit profil albertson
slightli better current deal albertson specif state
purchas better prescript impli may given less purchas
econom
altogeth rad/albertson manag non-committ possibl remain
contract given legaci option join wbad albertson
option join wbad current given assum acquisit rite
aid goe possibl could lose contract may
repres annual revenu possibl retain
contract beyond expect retain combin contract
would see econom pressur upon renew either situat
march move major technolog asset chang
healthcar legaci also contribut asset new entiti
chang blackston remain term
synergi bring two busi togeth expect gener
synergi end year compani plan ipo busi
depend market condit nine month follow ipo would spin-off
chang sharehold
manag guidanc see busi contribut ebit
ownership dis-synergi due mck share interest
expens entiti
tax effici manner busi
remain technolog asset move core drug distribut
busi alongsid covermym legaci electron healthcar record busi
sold allscript deal close begin octob mckesson
guidanc assum contribut ei busi ep tie
ei busi assum remaind off-set share
repurchas complet among chang assumpt
chang compani ep guidanc
medical/surg segment threat amazon
addit drug distribut industri medical/surg segment could
also at-risk amazon recal industri section accord wsj amazon
talk hospit possibl provid new solut improv effici among
thing mckesson busi larg gear toward physician practic howev
physician practic could easili order consum product amazon given
dynam add risk medical/surg segment beyond wsj
articl survey physician practic survey indic mid singl digit
percentag current util amazon purchas consum product time
respond expect purchas consum product amazon
physician practic survey consum expect purchas amazon
part portfolio capit alloc polici done host acquisit
year recent acquisit rxcrossroad compani acquir
cash net present valu increment cash tax benefit
rxcrossroad provid commerci support custom dispens logist
servic pharmaceut manufactur transact expect ep
accret third year follow close transact
beyond rxcrossroad compani also complet six transact prior rxcrossroad
compani indic transact complet would bring ep
accret year contribut would nomin manag note
would addit invest spend drive accret year
ep accret would linear
recent result
report result februari compani adjust ep
best street estim howev beat driven pure discret tax
item lower compani tax rate assum normal tax rate
in-lin compani guidanc quarter suggest ep revenu
came ahead street view margin gener in-lin
street view ebit grew due much easier comp
year ago period one-tim charg impact ebit growth
closer gener in-lin prior quarter y/i growth
altogeth suggest underli market chang significantli
importantli beyond compani result quarter compani overal
commentari marketplac manag note sell-sid gener price
continu remain competit less volatil brand inflat slightli
in-lin compani view although manag note brand inflat less
critic compani profit
consum product expect purchas amazon barclay servic
expect adjust ep compar
ep outlook compani initi provid earn call gener
increas ep driven larg lower tax share repurchas compani
distribut solut margin expect origin outlook
bp manag attribut mix shift separ contribut chang
healthcar expect compar origin view
lower outlook due deferr custom purchas within imag busi
compani share repurchas author remain
factor consid
canada gener price initi canadian provinci govern
go effect april start price reduct
commonli use gener product impact part mck canada busi
segment compani process close sell retail
pharmaci locat recal initi caus reimburs pressur uk
beyond compani anticip
tax indic expect lower tax rate move forward howev
compani expect overal effect tax rate higher recal
compani record variou discret tax item lower compani
effect tax rate well impli guidanc compani
updat guidanc see tax rate impli see tax
rate suggest go-forward rate may rang
continu trade pe valuat low end histor rang
compani face variou headwind form drug price concern brand
gener product elev level gener deflat concern regard amazon
within drug distribut market addit compani medical/surg busi
gear toward physician offic also suscept amazon similar natur
cah product given factor believ stock stall near term
initi equal weight rate pt base ep
 annual revenu model mil mckmckmckrevenu revenuenorth american pharma distribut growthnorth american pharma distribut total revsnorth american pharma distribut annual gross profit mil mckmckmckgross profit gross profit formula distribut technolog gross growthdistribut technolog gross gp margindistribut technolog gross profit annual oper profit mil mckmckmckoper profit ebit ebitdistribut technolog incom expens newco hcit affili growthdistribut technolog incom expens newco hcit affili ebit ebit margindistribut technolog incom expens newco hcit affili incomenmnmnmnmnmnmnmnmtot ebit barclay servic
 annual incom statement ex amortizaiton lifo one-tim ex amort one-tim addback excl intang asset oper expens incom chang expens expens rate minor interest check ep fulli dilut share growth ex amort one-tim expens per barclay servic
 annual revenu model mil mckmckmckrevenu revenuenorth american pharma distribut growthnorth american pharma distribut total revsnorth american pharma distribut annual gross profit mil mckmckmckgross profit gross profit formula distribut technolog gross growthdistribut technolog gross gp margindistribut technolog gross profit annual oper profit mil mckmckmckoper profit ebit ebitdistribut technolog incom expens newco hcit affili growthdistribut technolog incom expens newco hcit affili ebit ebit margindistribut technolog incom expens newco hcit affili incom -- -- nmnmnmnmnmnmtotal ebit barclay servic
 annual incom statement mil ep ep ex amortizaiton lifo one-tim ex amort one-tim addback excl intang asset oper expens incom chang expens expens rate minor interest check ep fulli dilut share growth ex amort one-tim expens per barclay servic
diplomat pharmaci inc dplo quarterli annual ep usd
consensu number thomson reuter
initi coverag overweight rate
initi coverag diplomat pharmaci overweight rate price
target base ep estim stock
punish sinc earn came touch light bottom line due
higher expect interest expens compani undergo believ
posit transform toward higher margin busi addit pbm asset
believ new combin specialti pharmaci asset coupl pharmaci
benefit manag yield revenu synergi time via greater access
exclusive/limit drug possibl effect manag pharmaci trend beyond
revenu synergi cost synergi achiev given rel
low ebitda quit materi overal busi separ compani either
renew move new distributor septemb could yield better
econom beyond take altogeth initi ep guidanc
came due higher expect interest expens transform
busi remain track upcom tailwind help bolster growth lead us
overweight rate
pbm asset bring plenti growth
dplo acquisit np ldi toward end help revamp
overal busi less reliant core dispens specialti drug bring
signific margin expans busi revenu compon pale
comparison core specialti busi pbm revenu vs
specialti pharmaci rev profit pbm busi far outweigh core
put perspect pbm expect gener ebitda growth
inorgan core busi ebitda grow cost synergi
acquir asset gener ebitda growth beyond acquir asset
dplo could also see benefit renew switch current distribut
contract could provid increment margin expans addit
free cash flow gener pbm compani abl reduc interest
expens one key lower expect ep guidanc
share dplo volatil follow guidanc call higher
interest expens rate pressur ep street expect howev ep
light believ dplo rebound doubl digit ep growth compani de-
lever altogeth believ multipl appropri ep
specialti pharmaci move pbm world
diplomat evolv past year compani increasingli
move toward servic type model particularli compani began face increas
amount pressur relat dir fee compani announc
acquisit ldi integr pharmaci servic full servic pbm novemb
dplo announc would acquir compani cash
common stock ldi expect gener revenu
ebitda base compani paid gross purchas price
management note compani expect gener tax shield npv
translat price factor year expect synergi
compani total payment repres
acquir ldi compani essenti move complet pbm space
conjunct compani acquisit np ldi middl market pbm servic
live primarili focus commerci market base data provid
compani ldi three year compound-annual-growth-rate revenu ebitda
prescript member live manag note expect ldi
see ebitda growth similar natur three year compound-annual-growth-rate would closer
includ synergi
note synergi relat deal expect year
manag note specif cost relat synergi includ
revenu synergi expect deriv combin entiti addit
compani expect achiev synergi three year cost relat
cadenc synergi year manag expect synergi begin build
culmin save end
take acquisit ldi np togeth new pbm vertic bring total revenu
ebitda util compani estim non-
client chang result revenu come quarter
impli revenu benefit term cadenc
profit similar natur normal pbm profit back-half weight
ultim deal help diversifi diplomat core specialti pharmaci busi
like bolster futur ebitda growth given differ margin profil two
note financi benefit deal complet end
combin specialti pharmaci middl market pbm bring benefit
beyond financi accret diplomat may abl better access limited-distribution/
exclus drug manufactur given combin pbm addit
compani may capabl manag drug trend middl market employe
strong control specialti drug trend
acquisit core dplo
note dplo close coupl acquisit brought
compani pbm world howev beyond acquisit dplo also done
host acquisit key growth particularli profit
enhanc perspect dplo acquir number smaller specialty/infus
pharmaci throughout also acquir hub servic busi
contribut acquir busi excl pbm busi rel small
revenue/ebitda contribut acquisit carri significantli higher margin
may help compani off-set margin pressur core specialti pharmaci busi
note collect ltm revenu acquisit time
acquisit complet would repres revenu
acquisit complet
one biggest headwind past year diplomat impact direct
indirect remuner dir fee remind accord diplomat manag
dir fee appli specialti pharmaci tail end caus
major revis ebitda expect ebitda compani adjust
contract term move psao contract direct contract one key
payer given close major medicar part contract compani
expect dir fee consist dir fee impli
worst dir fee perspect beyond diplomat indic
futur contract expect take account differ retail
specialti pharmaci remain seen pharmaci benefit manag
switch new contract methodolog distinct specialti
pharmaci posit mitig neg impact dir fee beyond
current diplomat contract
manag indic inflat within specialti drug core
compani oper mid singl digit rang similar overal brand
market also examin inflat level specialti drug believ
key drug diplomat seen inflat rate remain rel steadi
slightli rel number drug price increas declin
y/i basi
integr mil cash mil mil yr mil cash day mil cash mil stock mil mil cash mil conting considerationna barclay servic
inflat rate specialti drug
diplomat recent announc ceo phil hagerman would retir jeff park
would take interim ceo manag indic move
plan exact time unknown given see major concern
retir mr hagerman addit appoint jeff park
interim ceo compani gain former pbm execut abl lead
compani transit period pbm busi becom
promin piec busi compani continu search perman ceo
compani result slightli better in-lin street estim
compani post revenu street ep compar
street view lower ep guidanc larg function higher interest
expens envis street
diplomat provid full guidanc result compani expect
revenu adjust ebitda ep diplomat
provid revenu adjust ebitda guidanc prior investor confer
drugltm sale drug price barclay servic
januari time preliminari guidanc well receiv given adjust ebitda
well consensu time fulli updat guidanc ep fell short
street consensu differenti seemingli due higher
anticip interest rate expens compani expect interest expens
tax rate share outstand
share dplo volatil follow guidanc saw higher
interest expens rate caus ep come street howev ep
light believ compani rebound doubl digit ep growth compani de-
lever altogeth believ multipl appropri ep
dplo miladjust miladjust incom attribut miloth notesinclud ldi np barclay servic
diplomat pharmaci annual incom statement comp op addback addback check excl intang asset item exclud net ens rate interest check ep fulli dilut share growth per barclay servic
diplomat pharmaci quarterli incom statement comp op addback addback check excl intang asset item exclud net ens rate interest check ep fulli dilut share growth per barclay servic
express script esrx quarterli annual ep usd
consensu number thomson reuter
initi equal weight rate pt
initi coverag express script equal weight rate pt
base pro-forma ep estim unadjust ep
share flat line past year due contract
overhang howev offici decid leav esrx
creat greater clariti earn power esrx move forward
clariti esrx essenti year fill earn hole remain seen
compani return top-line growth compani signific cost cut
de-lever readili accomplish given compani strong free cash
flow resourc tie compani seen claim growth shrink
past year larg due difficulti tie medco merger integr
remain seen compani emerg net winner claim growth given
factor lead equal weight rate
de-lever cost cut share repo need top-lin growth
note signific earn hole come contract
set expir end esrx provid transit servic
possibl beyond repres compani profit given compani
primarili focus re-align compani cost structur follow loss
howev note common theme past year
compani work way integr medco compani cut
cost past year sg sinc enterpris valu
initi also expect gener mil annual run rate save
supplement share repurchas account larg major ep
growth past year esrx de-lever due pend
contract loss applaud move reward sharehold re-ori
busi believ critic return top-lin growth note
compani may beneficiari chang healthcar landscap may help
bolster top-line growth howev remain seen come fruition given
believ share stall somewhat
price target base pro-forma ep
unadjust ep pe multipl lower end rang
believ appropri given overhang loss expect
one core theme express script past year continu
concern around largest custom way background litig
script claim overcharg work
good faith market price check actual litig continu make way
court relationship two compani essenti fray
point announc compani would launch compet pbm
ingeniorx support
disclosur express script relat busi profit
